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SUMMARY
Colon cancer represents one of the major causes of death in the 
Western hemisphere, being responsible for over 60,000 deaths per year in the 
U.S. Over the past 50 years, the hypothesis of the adenoma-carcinoma 
sequence, which proposes that benign colonic polyps are the precursor 
lesions of malignancy, has been accepted. Any study of the possible 
carcinogenic mechanisms in colon cancer therefore should also be directed 
to the precursor lesions - the benign polyps.
The polyamines putrescine, spermidine and spermine, are low molecular 
weight aliphatic amines intimately involved in cell proliferation and 
^differentiation. Since the 1970s, it has been noted that polyamine 
concentration is higher in a number of malignancies when compared to normal 
tissue. The two main rate-limiting enzymes in the polyamine biosynthetic 
pathway are ornithine decarboxylase (ODC) which catalyses the conversion of 
ornithine to putrescine, and S-adenosylmethionine decarboxylase (AdoMetDC) 
which acts as an ami nopropyl donor in the conversion of putrescine to 
spermidine and spermidine to spermine. ODC and AdoMetDC are highly 
inducible enzymes, their activity rising early in oncogenesis in certain 
model systems. Regulation of both enzymes occurs at a number of levels. 
Since the polyamines are so necessary for normal growth and differentiation 
it is likely that deregulation of the polyamine biosynthetic pathway is a 
major factor in carcinogenesis.
Both polyamine content and enzyme activity rise early in rodent colon 
when exposed to known carcinogens and bile acids. Polyamine concentration 
is elevated in human colon cancer compared to normal mucosa. Several 
workers have shown that ODC and AdoMetDC activity is greatly increased in 
both benign colonic polyps and cancer implying that activation of the 
polyamine pathway may be involved in the conversion of benign to malignant 
polyps.
A study of the control of the ODC and AdoMetDC genes starts with a 
knowledge of the chromosomal loci for these genes.
The purpose of this study was: 1) To map the ODC and AdoMetDC genes; 
2) Study expression of the ODC gene in colon neoplasia (carcinoma and 
polyps) in relation to ODC enzyme activity; 3) Investigate whether any
10
amplification or rearrangement of the ODC gene was responsible for increased 
expression; and, 4) Study similar genetic mutations of the AdoMetDC gene 
in colon neoplasia.
The DNA from 31 mouse/human cell hybrids was digested with PstI, and 
the DNA from 37 hybrids digested with Hlndlll. Fragments were separated by 
agarose gel electrophoresis, transferred to nylon filters, probed with a 
radiolabelled human cDNA ODC clone and autoradiographs obtained. By this 
method, the ODC gene was mapped to sequences on chromosome 2 and 7q31-+qter. 
In both PstI and Hindlll digests the sequences on chromosome 7 were less 
prominent under high stringency conditions. The locus on chromosome 2 was 
defined by in situ hybridisation: of 1987 metaphase sets examined, 361
silver grains were seen with 16.1% touching chromosome 2. Thirty-one 
percent of the grains on this chromosome were located at 2p25 with no 
significant hybridisation to chromosome 7. The locus on 2 was designated 
0DC1 and that on 7 0DC2.
AdoMetDC was also mapped by somatic cell hybrid techniques: DNA from 
38 somatic cell hybrids was digested with PstI and separated in a similar 
manner to that described for ODC. Two loci for AdoMetDC were found-one on 
chromosome 6 (referred to as AMD 1). and the other at Xq22 - Xq28 (AMD 21.
The ODC gene locus on chromosome 2 was seen to be polymorphic, 3 
consistent banding patterns being seen. Allele frequencies were calculated 
to conform to the Hardy-Weinberg law with p = 0.28 and q = 0.72.
ODC gene expression was studied in 18 isolated colorectal tumours and 
adjacent normal mucosa and 6 polyps. The expression of the housekeeping 
enzyme triose phosphate isomerase (TPI) was used as an internal control. 
In all cases a single ODC RNA transcript was seen measuring 2.2 kb. ODC 
expression was consistently increased in tumours compared to mucosa by a 
mean of 4.2-fold and in polyps by a mean of 3.2-fold (p < 0.001). No 
correlation was found between ODC expression and site of tumour, stage, or 
degree of differentiation.
In 15 patients paired samples from the same patient were analysed for
both ODC activity and ODC expression. Although all samples showed a
significant increase in activity and expression when compared to mucosa, no 
correlation was seen between the two parameters for the same sample.
ODC expression was also increased in gastric cancer, leiomyosarcoma
and liposarcoma, but not to the same degree as in colorectal neoplasia, 
suggesting tissue specific gene regulation.
11
ODC DNA analysis was performed on 18 colorectal carcinomas and seven 
polyps. No amplification of either locus was seen to account for the 
elevated expression. No consistent rearrangement of the ODC gene was seen 
in colorectal neoplasia. No amplification of ODC was seen in 
leiomyosarcoma, liposarcoma, breast, lung, or gastric cancer. Analysis of 
AdoMetDC DNA was performed on 13 samples of colorectal cancer and five 
polyps. No amplification or rearrangement was seen.
No correlation was noted between ODC and amplification of NMYC, or 
between ODC expression and expression of IGF-2.
Elevation of ODC expression and activity seems to be a consistent 
finding in colorectal carcinoma and polyps in this and other studies. The 
expression of ODC in early polyps suggests a role for ODC in the early 
events of oncogenesis. The ODC gene is influenced by hypomethylation and 
mutated ras genes, both of which are known to occur early in the cascade of 
colon cancer formation proposed by Vogel stein. The stereospecific 
interaction of the polyamines with DNA may evoke further genetic 
deregulation along this cascade.
The precise role of ODC regulation in colorectal neoplasia is still 
unclear. It is apparent that increased expression is not due to 
amplification of the gene as in other systems, but may be due to altered 
transcription rate or mRNA stability. Similarly, it is unclear how elevated 
activity is produced at the tissue level. As no correlation was found 
between expression and activity, post transcriptional mechanisms must also 
be in operation, such as altered forms of ODC protein. An example would be 
the GTP-activatable form of ODC which has recently been isolated from colon 
tumours.
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1. INTRODUCTION
1.1 Epidemiology of Colon Cancer
Colorectal cancer is a major cause of disease in the Western 
world. There are estimated to be 157,000 new cases in the United 
States in 1991 and 60,000 deaths due to the disease. Although the 
disease is common in the U.S., it is even more prevalent in 
Scotland.1’3
Environmental factors are thought to play an important part in 
the incidence of colorectal cancer. Immigrants from Japan and black 
Africa, where the disease is relatively infrequent, show an increased 
risk when living in the U.S.2 The low incidence in some 
underdeveloped countries3 has prompted interest in possible 
aetiological factors. In the early 1970s, D.P. Burkitt proposed that 
the higher intake of fibre in the diet in several African countries, 
with consequent decreased transit time through the gut, was 
responsible for altered colorectal cancer rates. This was attributed
4 5to a possible dilutional effect on carcinogens in the stool. '
Faecal bile acids are thought to be carcinogenic to the colon 
mucosa. Bile acids can act as tumour promoters in animal models.6 
Hill, et al.,7 found a higher faecal bile acid concentration in 
patients with large bowel cancer when compared to patients with other 
diseases, although this result could not be repeated by Murray, et 
al.8
The bile acids produced by the liver are converted by intestinal 
flora to secondary bile acids which are carcinogenic.9 A higher ratio 
of anaerobic to aerobic bacteria in the colon has been demonstrated 
in countries with a higher incidence of colon cancer.7,10
Dietary intake of fat and red meat is also positively correlated 
with colon cancer incidence.11,12 It is possible?that high fat and low 
fibre intake act together in increasing the risk of colon cancer. 
Diets high in fat also cause a higher excretion of bile acids.9
Alcohol intake has also been associated with high rectal cancer 
rates.2,6 On the other hand, increasing selenium2,6 and calcium13 in 
the diet may have a protective role against colon cancer. Lipkin and 
Newmark14 demonstrated lower proliferative activity in colonic crypts
13
when oral calcium supplements were administered.
It appears then that multiple environmental factors may 
influence the incidence of colon cancer in a particular population. 
Strong15 has proposed that the response to environmental agents may 
differ because of genetic variation, cancer being a genetic disease 
at the cellular level. Hill, et al.,16 in particular reference to 
colorectal cancer, put forward a hypothesis that the environmental 
carcinogen can only cause progression from normal mucosa to 
neoplastic polyp to carcinoma (the adenoma-carcinoma sequence) when 
the person is genetically predisposed to the disease.
1.2 The Adenoma-Carcinoma Sequence
The importance of the study of colonic polyps in relation to 
colonic cancer rests on the increasing evidence that these are the 
precursor lesions which progress to carcinoma.
The word polyp is derived from the Greek polypous meaning morbid 
excrescence. The classification of neoplastic polyps currently used 
divides adenomas into tubular, villous and tubulo-villous types.17'19 
The incidence of malignancy is increased in villous compared to 
tubular adenomas, the percentage found containing malignancy being 41 
and 5, respectively.19 Cuthbert Dukes recognised that there was a 
strong correlation between "simple tumours" and subsequent 
development of colon cancer.20 The chance of malignant transformation 
also increases with the size of the polyp-polyps 1-2 cm in diameter 
have a 10% incidence of carcinoma, whereas 46% of polyps over 2 cm 
will contain malignancy.19,21 Malignant potential also increases as 
the degree of dysplasia progresses from mild to severe.19 Most of the 
work detailing the adenoma-carcinoma sequence was performed by Basil 
Morson at St. Mark's Hospital in London. This data is supported by 
Shinya and Wolff22 and Love.23 Cole and McKalen24 injected tritiated 
thymidine into a patient with familial polyposis prior to colectomy 
and found that the normal zone of proliferating cells lies at the 
bases of the crypts of Lieberkuhn. Development of the adenoma is 
preceded by a hyperproliterative period when the zone shifts to the 
upper part of the crypt. Autoradiographs of adenomas reveal the 
labelled cells to be situated at the periphery of the polyp. Thus,
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in adenomas, there is a loss of normal growth control mechanisms.25 
This finding was also observed by Deschner and Lipkin.26
Alterations of cell kinetics in neoplasia has been divided into 
stages by Deschner27'28 and Lipkin.29 In Stage I, there is an 
extension of the proliferative component to the luminal surface of 
the crypt. A Stage II abnormality comprises a shift of DNA synthesis 
from the base to the upper and middle thirds of the glands. 
Bleiberg, et al.,30,31 also using tritiated thymidine, found a larger 
S phase duration in colonic cancer and polyps compared to normal 
tissue.
It is now generally accepted that an adenoma-carcinoma sequence 
exists, that polyps should be regarded as premalignant lesions, and 
that polyp removal therefore is a method of cancer prevention. The 
continuum of epithelial neoplasia begins with an adenoma of varying 
degrees of dysplasia, this is followed by the appearance of 
cytologically malignant cells, but still confined to the crypt. This 
can be classified as an intraepithelial carcinoma.32 The malignant 
cells then invade the lamina propria which separates the crypts of 
Lieberkuhn, termed intramucosal carcinoma. It is only when the 
mucosa is breached that the tumour becomes invasive and potentially 
metastatic.
1.3 The Staging of Colorectal Cancer
In 1932, Sir Cuthbert Dukes at St. Mark's Hospital developed a 
staging system for carcinoma of the rectum.33 Stage A represented 
those cases where the carcinoma was limited to the wall of the 
rectum; in Stage B, the carcinoma had spread through to the extra- 
rectal tissues; and in Stage C, regional lymph nodes were involved. 
Survival decreased as the stage of disease became more advanced.
This staging system has also been applied to colon cancer and 
several modifications of Dukes' original schema have been used. The 
staging system used in this thesis is that proposed by the 
Gastrointestinal Tumour Study Group (GITSG).
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Colon34
A - Invasion of the mucosa.
B, - Invasion of the muscularis mucosa (siub-mucosa).
b 2 - Penetration to or through the serosa without nodal
involvement.
c, - One to four nodes involved.
c2 - Five or more nodes involved.
Rectum35
A and B, - As for colon cancer.
B2 - Extension of the tumour through the rectal wall without 
nodal involvement.
^  and C2 - As for colon cancer.
In this system, the depth of penetration of the bowel wall
did not affect the classification of stage C tumours.
1.4 The Genetics of Colorectal Neoplasia
Although environmental factors are important in the oncogenesis 
of colon cancer, they are believed to operate on the underlying 
genetic predisposition for the disease.15,16 The contribution of 
inherited factors to the origin of colorectal cancer is poorly 
understood, but begins with the well-defined autosomal dominant 
conditions. Familial polyposis, now called familial adenomatous 
polyposis, is a condition in which the colon and rectum are carpeted 
with hundreds of polyps.36 Carcinoma will develop in 100% of affected 
persons. In 1882, Harrison Cripps described polyposis in a brother 
and sister.37
Following Cripps' report, Smith,38 Bickersteth,39 and Handford40 
described cases of multiple polyposis of the lower bowel. Both 
Smith's and Bickersteth's cases appeared to be familial in origin. 
The case Handford described was notable in that carcinoma occurred 
simultaneously with multiple polyps.
Cockayne, in 1927,61 was the first to suggest a Mendelian 
dominant mode of inheritance. In 1930, Dukes42 put forward the idea 
that in polypsis coli, colon cancer itself is not inherited, rather 
it is a tendency to epithelial proliferation leading to polyps and 
later to cancer which is inherited. Lockhart-Mummary later also
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embraced this idea.43
In 1939,44 Lockhart-Mummary and Dukes made the insightful 
hypothesis that polyposis arose as a result of gene mutation. Part 
of our understanding of the adenoma-carcinoma sequence begins with an 
observation of the natural history of familial polyposis.
In 1950, E. J. Gardner produced the first of several papers 
concerning the syndrome which bears his name and the genetics of 
colon cancer became more complex.45 In this syndrome, polyposis is 
associated with extra-colonic manifestations such as epidermoid 
cysts, desmoid tumours, and osteomas.
Blair and Trempe46 and later Lewis, et al.,47 described 
congenital hypertrophy of the retinal pigment epithelium in Gardner's 
syndrome.
Various other inherited syndromes associated with multiple 
adenomatous polyps have been described, for example, Turcot's 
syndrome, associated with neurogenic tumours48; Oldfield's syndrome, 
associated with multiple sebaceous cysts49; and Muir-Torre syndrome, 
associated with multiple skin tumours and other malignancies50’52. 
Cowden's53 syndrome and Peutz-Jeghers54,55 syndrome also result in 
multiple polyposis, but of the hamartomatous, not adenomatous type. 
Cronkite-Canada syndrome56 results in inflammatory polyps and is 
occasionally associated with colorectal cancer.54
Gardner has raised the issue that familial adenomatous 
polyposis and Gardner's syndrome may be variations of the same 
disease, transmitted by the same genetic defect.57
Alfred Warthin, in 1913, was the first to recognise the 
phenomenon of the cancer family.58 Since then, Lynch has studied 
numerous kindreds extensively with the recognition of two types of 
hereditary non-polyposis colorectal cancer: cancer family syndrome
or Lynch syndrome II comprises early onset proximal colonic cancer 
and extra-colonic adenocarcinomas and Lynch syndrome I (hereditary 
site specific colon cancer) which has all of the above 
characteristics but is not associated with extra-colonic cancer.59'67 
Aside from the autosomal dominant conditions, colon cancer exhibits 
familial aggregations, in that family members of the index case 
appear to have a higher incidence of the disease.
j Duncan and Kyle68 investigating familial colon cancer in
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northeast Scotland, found 16% of patients with colon cancer had a 
first degree relative with the disease, but did not find them to be 
younger than patients without a family history. Lovett,69'70 in 
London, found a three-fold increase in death rate from intestinal 
cancer among relatives over that which would be expected in the 
general population, confirming what Macklin had found in an Ohio 
population.71
Not only does the tendency to form multiple polyps appear to be 
inherited: Richards and Woolf72'73 have noted that solitary polyps of 
the colon and rectum also appear to be inherited in a mendelian 
dominant pattern in some cases.
Although it has been said that approximately 5% of colon cancer 
is inherited,74 Burt, et al.,75 presented evidence that sporadic 
adenomas and colon cancers are inherited much more commonly. Their 
analysis concerned a large Utah kindred with no recognisable 
inheritance pattern. One or more adenomatous polyps was found in 21% 
of family members but in only 9% of controls. This excess of 
discrete polyps and cancers suggested to them the presence of an 
autosomal dominant gene for susceptibility. They conclude that a 
major step would be the genetic mapping of the locus for 
susceptibility to colon cancer.
Cytogenetic abnormalities observed in colorectal cancer 
specimens may lead investigators to the locus for this gene.
Numerous chromosomal abnormalities have been seen in colon 
cancer. These include 12q-, +7, +8, +12, 17(qll)76, partial trisomy 
of 1 q77 monosomy 17p, monosomy 18, monosomy 20q, trisomy 13, monosomy 
lp, and trisomies X and 8q.78 Levin and Reichmann79 also report 
trisomy 13, 19, 20, 21, loss of 17 and structural alterations of 1 
and 5. Abnormalities of chromosomes were also seen by Shabtai, et 
al.80 In polyps, the most frequent karyotypic change is +8 and -20.81 
Attempts have been made to characterise chromosomal changes in 
familial polyposis and Gardner's syndromes.82 Increased tetraploidy 
was seen in both conditions and has also been seen in non-hereditary 
adenomata.83
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1.5 Gene Mutation and Activation in Colon Cancer
Altered expression of several genes occurs in colon neoplasia. 
Increased Ki-ras and Ha-ras oncogene expression occurs in both 
colorectal polyps84 and carcinomas.84'85 C-fos and c-myc expression is 
also increased in colon carcinomas.85 Tricoli, et al.,86 found 
significantly increased insulin-like growth factor 2 (IGF-2) mRNA 
levels in 50% of rectal and rectosigmoid cancers but not in cancers 
from other sites in the colon. The activation of Ki-ras in colon 
carcinoma occurs by two different point mutations of the same codon.87
Altered DNA methylation results in altered expression of mRNA.88 
Increased ras oncogene expression in colon cancers may also be 
due to hypomethylation. Feinberg and Vogel stein89 demonstrated hypo- 
methylation of the Ha-ras oncogene in five of seven colon cancers. 
Ki-ras hypomethylation occurred less frequently.
1.6 Gene Happing and Its Importance in Cancer Research
Knowledge of the chromosomal locus of a gene is important in 
studying aspects of genetic regulation. Certain specific chromosomal 
aberrations have been associated with various cancers and are 
believed to be essential for oncogenesis to occur.90 An example would 
be Burkitt's lymphoma in which a translocation of a region of 
chromosome 8 occurs. The breakpoint on chromosome 8 appears to be 
crucial for the disease.91"93 This area involves the locus for c-myc, 
and its rearrangement to the vicinity of one of three immunoglobulin 
loci on chromosome 14, 2 or 22 results in deregulation of the myc 
gene. A similar activation of the oncogene c-abl, located on 
chromosome 9 occurs in chronic myeloid leukemia, in which a 9; 22 
translocation occurs. Such a translocation occurs in over 90% of
90-93cases.
The trigger for these chromosomal translocations may be their 
proximity to known fragile sites. Expression of fragile sites occurs 
by altering the concentration of folic acid and thymidine in culture 
media.92 Certain fragile sites coincide with breakpoints involved in 
the rearrangements of several neoplasias. C-mps has been mapped to
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8q22, the breakpoint in acute myeloblastic leukemia; the proto­
oncogene c-ets-1 has been mapped to Ilq23-q25, a region involved in 
a breakpoint in acute monoplastic leukemia. Both 8q22 and llq23 are 
the sites of heritable fragile sites.94
Gene mapping also allows study of diseases in which oncogenesis 
may occur by the deletion of chromosomal material. In 1971, Knudson 
developed the two hit theory of neoplasia in^which he stated that 
mutations of both the maternal and paternal chromosomes are necessary 
for neoplasia to occur.95 In the familial case, a germ-line or 
constitutional mutation is followed by a somatic mutation of the 
normal chromosome, which unmasks the disease locus. In sporadic 
cases, two somatic mutations at the disease locus would account for 
the disorder. His hypothesis was subsequently shown to be true for 
both retinoblastoma96,97 and Wilms tumour.98 This loss of genetic 
material has been termed, "loss of heterozygosity". The deletion in
retinoblastoma occurs at 13ql4, to which has also been mapped the
gene for esterase-D, an enzyme deficient in retinoblastoma patients. 
The Wilms tumour locus has been mapped to llpl3 where the gene for 
catalase also resides. Again, deficiencies of this enzyme occur in 
some cases of Wilms tumour.90
Thus, the knowledge of the gene map is vital to understanding 
deregulation of certain genes and is one of the first steps to
understanding the role of a gene in disease.
Gene amplification is another genetic alteration which is 
involved in neoplasia and tumour progression. Multiple gene copies 
of the oncogene N-myc which is located at 2p23-24 occur in
neuroblastoma. Amplification of N-myc is related to advanced stage 
and poorer prognosis in this disease.99 Mouse adrenocortical tumours 
contain amplified c-Ki-ras oncogene sequences. Amplified c-myc 
(normally present on chromosome 8) has been found on chromosome X in 
the colon cancer cell line C0L0-320.100 Gene amplification may also 
predict response to therapy, for example, resistance to methotrexate 
is determined by amplification of the dihydrofolate reductase gene.101
1.7 DNA Polymorphisms
Based on studies of the j8-globin cluster in humans, it has been
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estimated that the human genome contains 3 x 107 sequence variants or 
one every 100 base pairs.102 This would result;in approximately 106 
sequence polymorphisms per chromosome. These variations between 
individuals have been termed restriction-fragment-length- 
polymorphisms (RFLPs)103 and can be identified on Southern 
analysis.104 Polymorphic loci can result from additions or deletions 
of DNA, genetic rearrangements, or base-pair substitutions at the 
restriction endonuclease recognition site. The identification of 
RFLPs for a given gene may be useful not only as a marker but in 
understanding the phenotypic expression of that gene. Polymorphic 
markers can be transmitted in a Mendelian fashion.
Figure 1 illustrates how RFLPs are detected. DNA is isolated 
from several individuals and digested with a restriction 
endonuclease; separation of the fragments in an agarose gel and 
subsequent Southern blotting104 and hybridisation with a radiolabelled 
probe results in a different blotting pattern for each individual. 
Because of altered restriction sites in these individuals, different 
areas of DNA are recognised by the probe. It can be seen that person 
A and person C are both homozygotes, whereas B is the heterozygote.
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DETECTION OF DNA POLYMORPHISMS
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Figure 1
Detection of DNA Polymorphisms in Humans 
DNA is isolated From individuals, cleaved with restriction endonuclease, and 
fragments blotted using the Southern technique. The blot is hybridised to 
a radiolabelled probe which recognizes a specific site of DNA (indicated by 
black bar). The restriction sites are indicated by arrows. The normal 
pattern of restriction sites is seen in person A. In person C, a 
restriction site has been lost due to mutation (e.g., single base pair 
substitution DNA or rearrangement). Thus, the probe recognizes a fast 
migrating band in person A, a slowly migrating band in person C, and in B, 
the heterozygote, both slow and fast bands.
1.8 The Polvamines in Cancer
Cancer is characterised by uncontrolled growth and spread of 
abnormal cells. Normal cellular mechanisms of growth become 
disordered and deregulated. A group of low molecular weight 
aliphatic amines - the polyamines - have been shown to be essential 
for normal cell growth and proliferation.105"111 The polyamines 
comprise putrescine, spermidine, and spermine.
Putrescine
H2N-CH2-CH2-CH2-CH2-NH2
Spermidine
H2N-CH2-CH2-CH2-NH-CH2-CH2-CH2-CH2-NH2
Spermine
H2N-CH2-CH2-CH2-NH-CH2-CH2-CH2-CH2-NH-CH2-CH2-CH2-NH2 
Anthony von Leeuwenhoek, in 1678,112 was the first to recognise 
a crystalline substance in semen which precipitated: he termed this 
'semenstuf'. Vauquelin was studying the clotting properties of semen 
and noted crystallisation of a substance.113 It was not until 1924 
that spermine and spermidine were synthesised by Rosenheim.114 The 
precursor of spermidine, putrescine, was isolated from vibrio cholera 
in 1887.115
The enzyme ornithine decarboxylase (ODC, EC 4.1.1.17) catalyses 
the first and rate limiting step of polyamine biosynthesis, namely 
the conversion of ornithine to putrescine.
The polyamines appear to be essential for periods of 
proliferation in a tissue. An enhanced accumulation of putrescine in 
regenerating liver in response to tissue loss was found to be due to 
a 100- to 500-fold increase in ornithine decarboxylase activity.110 
Increased ornithine decarboxylase activity is also seen in kidneys 
following contralateral nephrectomy.110 Further support for the 
importance of the polyamines in cell division was provided by the 
observation that polyamine synthesis is enhanced during the late G, 
and early S phases of the cell cycle.111
A major breakthrough in polyamine research was the discovery by 
Metcalf, et al.,116 of an irreversible inhibitor of ornithine 
decarboxylase, alpha difluoromethylornithine (DFMO). Since then, the 
biosynthetic pathway of the polyamines has been elucidated (Figures
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2 arid 3).109-117
S-adenosylmethionine decarboxylase (AdoMetDC, EC 4.1:1.50) 
introduces decarboxylated S-adenosylmethionine into the pathway, 
where it acts as a donor of aminopropyl groups for the conversion of 
putrescine to spermidine and spermidine to spermine. S-
adenosylmethionine is essential to polyamine biosynthesis in its 
decarboxylated form. The aminopropyl transferases spermidine
synthase (EC 2.5.1.16) and spermine synthase (EC 2.5.1.22) (3 and 4 
in the diagrams) are regulated by the availability of decarboxylated 
S-adenosylmethionine and thus AdoMetDC regulates a key step in the 
pathway.
Both ODC and AdoMetDC are under strict negative control by the 
polyanrines.117,118 Polyamine metabolism appears to be cyclic in nature 
(Figure 3). Through consecutive N'-acetylation and oxidation 
reactions, spermine can be converted to spermidine and spermidine to 
putrescine. In the diagram, (5) represents spermidine/spermine N'- 
acetyltransferase and (6) polyamine oxidase.
S-methylthioadenosine (MTA), a by-product of the polyamine 
pathway is also a feedback inhibitor of spermidine and spermine
synthases. MTA is cleaved by MTA phosphorylase restoring the adenine
and methionine pools.
Both ornithine decarboxylase and S-adenosylmethionine 
decarboxylase are highly inducible, for example by trophic agents 
such as androgens, growth hormone and oestrogens. The stimulation of 
ODC usually peaks four hours after the administration of hormone,110 
or after hepatectomy.118 ODC has one of the shortest half-lives of 
any enzyme (10-30 minutes),118 AdoMetDC having a half-life of 20
119minutes to two hours.
The functions of the polyamines which have been described are 
manifold,110,120 and include membrane stabilisation, stabilisation of 
DNA, association of tRNA, stimulation of both DNA and RNA synthesis, 
binding of tRNA to chromosomes, and initiation of translation. The 
possible effects on DNA and protein synthesis are of great interest, 
and would explain the pivotal nature of the polyamines in cell 
growth. Many of the effects are attributable to the physiochemical 
attributes of the polyamines - the amino groups are largely
r ..
protonated and thus impart a flexibility of structure which allows
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interaction with the DNA molecule.106 In one model of the 
stereospecific interactions, polyamines bridge the minor groove of 
DNA with the positively charged amino groups of polyamines 
interacting with the negatively charged phosphate groups of the DNA 
backbone.121 Research on the role of polyamines in cancer began with 
Hamalainen in 1947 when he made the pioneering observations of 
increased spermine content of postmortem organs from patients who had 
died of different types of neoplasm.122'123 In 1971, Russell found 
increased urinary excretion of polyamines in patients with metastatic 
cancer.124
Further work by Russell and colleagues revealed urinary 
polyamines to be an indicator of response to therapy as levels fall 
following extirpation of the tumour.124,125 CSF polyamines have been 
used to measure response to treatment of medulloblastoma.126
High urinary polyamine content has been described for a variety 
of human malignancies including tumours of the gastrointestinal 
tract, respiratory system, urinary system, female and male 
reproductive system, breast, central nervous system and bone.123 
Elevated serum polyamines are also seen in the presence of several 
different cancers.123
The mouse skin tumour model of initiation and promotion has 
provided evidence of the essential role of ODC in carcinogenesis. In 
1976, O'Brien127 found a 250-fold increase in ODC activity five 
hours after application of 12-0 tetradecanoylphorbol-13-acetate (TPA) 
accompanied by a smaller, slower rise in AdoMetDC activity. His 
observations led him to believe that induction of ODC was an 
obligatory event in mouse skin carcinogenesis.
The addition of 1% DFMO to the drinking water of mice subjected 
to multiple applications of TPA reduced the incidence of papilloma 
formation by 90%.128
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The Polvamine Biosynthetic Pathway 
Ornithine decarboxylase (ODC) (1) catalyses the formation of putrescine from 
ornithine. S-adenosylmethionine decarboxylase (AdoMetDC) (2) catalyses the 
reaction yielding decarboxylated S-adenosylmethionine (dcAdoMet) from S- 
adenosylmethionine (AdoMet) which then acts as an aminopropyl donor to form 
spermine and spermidine: (3) spermidine synthase (4) spermine synthase.
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The Cyclic Nature of Polvamine Metabolism 
Ornithine decarboxylase (ODC).
S-adenosylmethionine decarboxylase (AdoMetDC).
Spermidine synthase.
Spermine synthase.
Spermidine/Spermine N'-acetyltransferase.
Polyamine oxidase.
MTA phosphorylase.
AdoMet synthetase.
AdoHcy - adenosylmonocysteine.
HCY - homocysteine.
KMTB - 2-keto-4-methylthiobutyrate.
MTRP - 5-methylthioribose-l-phosphate.
Inhibitors
DFMO - a-difluoromethylornithine - irreversible inhibitor of ODC.
MGBG - methylglyoxal-bis-(guanyl-hydrazone) - non specific inhibitor of 
AdoMetDC.
AdoDATO (S-adenosyl-l,8,-diamino-3-thioctane) - transition state analogic 
inhibitor of spermidine synthase.
1.9 Regulation of ODC and AdoMetDC
Because of their importance in cell growth and neoplasia the 
regulation of ODC and AdoMetDC have been the subject of intense 
research in the past 15-20 years, although AdoMetDC regulation has 
lagged behind. Such study was greatly facilitated by the cloning and 
later sequencing of the mouse gene for ODC,129'134 and the cloning of 
the bovine135 and rat136 AdoMetDC gene.
It is known that amplification of the ODC gene occurs in 
certain cell lines resistant to DFMO129,137 and arginine.138 Alhonen- 
Hongisto, et al., have shown that alterations in ODC gene copy number 
and gene rearrangements are related to altered tumourigenicity in 
Ehrlich ascites-carcinoma cells.139 Overproduction of ODC is not 
always associated with gene amplification however; in an L1210 
leukaemia cell line, a 60-fold excess of ODC was accompanied by only 
a two-fold gene amplification.140 McConlogue and colleagues have 
shown in several variants of cell lines which overproduce ODC that 
altered translatability of the ODC gene also occurs.141
Multiple levels of regulation of ODC occur. The down
regulation of ODC by the end product of the reaction - the 
polyamines-occurs both at the level of translation142'144 and by post- 
transcriptional145,146 and post-translational147 modifications. One of 
the post-translational modifications known to regulate ODC is the 
binding of ODC to an inhibitory protein which has been termed 
antizyme.148'154 Down regulation also occurs by changes in the rate of 
enzyme turnover,155 modification of the protein by phosphorylation,156 
conversion from an active to inactive form,157,158 anti enzyme binding 
causing enhanced enzyme breakdown,159,160 and induction of specific 
enzyme binding leading to enhanced breakdown.161
In the androgen-stimulated kidney162 and in transformed mouse 
fibroblasts,163 increased ODC activity was found to be due to an 
increase in the amount of ODC protein. The administration of the 
carcinogen 12-0-tetradecanoylphorbol-13-acetate (TPA) to hamster 
fibroblasts and mouse skin led to increased amounts of both mRNA and 
protein.164,165 In the mouse, two RNA transcripts exist measuring 2.2 
kb and 2.7 kb in size. They differ because of heterogeneity at the
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3' end.166
Regulation of AdoMetDC activity also occurs at multiple levels. 
AdoMetDC activity decreases in response to the administration of 
exogenous spermidine.119 This effect varies depending on the tissue 
studied,167 and it has been suggested that AdoMetDC exists in 
different forms in different tissues.168
Treatment with DFMO will result in an increase in both AdoMetDC 
protein169 and mRNA.170 Part of the increase in protein is accounted 
for by a slowing of degradation of the protein,169 but increased 
synthesis of mRNA also occurs.117 Increases in AdoMetDC activity due 
to trophic agents occurs by increased protein content due to 
stabilisation of the protein.171
The regulatory mechanisms of ODC and AdoMetDC in solid tumours 
have not been studied to date.
1.10 Polvamines and the Gastrointestinal Tract
Increased urinary polyamine levels have been reported for 
patients with colorectal cancer both disseminated172'174 and 
localised.175 Elevated serum polyamines have also been noted.176'177
The importance of polyamine biosynthesis in normal 
gastrointestinal tract physiology has been elucidated by Luk and 
others. For example, ornithine decarboxylase is increased in the 
intestine recovering from a chemotherapeutic insult,178 following 
jejunectomy,179 and during the intestinal adaption response to 
lactation.180 The normal maturation and recovery of the intestinal 
mucosa is abolished by DFMO leading to villous atrophy.178,181,182
Measurements of the polyamine content of colorectal cancers and 
polyps compared to normal mucosa revealed statistically significant 
increases in all types of colorectal neoplasia. Polyamine content in 
adenomas was as high as in carcinomas and tended to be greater for 
lesions having severe rather than moderate dysplasia.183,184 
Kingsnorth and colleagues185 found mean spermine and spermidine 
content of colorectal cancer specimens to be more than three times 
that of control mucosa and independent of site of tumour, stage of 
disease, and histological grade.
LaMuraglia, et al., have found a corresponding increase in ODC
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activity in both cancers and polyps of up to 320% of control. 
Similar elevations were noted for both benign and malignant
neoplasms.186,187 A salient paper by Luk and Baylin188 noted that 
ornithine decarboxylase activity was also higher in dysplastic 
compared to non-dysplastic polyps from familial polyposis patients. 
Porter, et al.,189 found a gradient of increased enzyme activity, the 
activity in polyps being between that of mucosa and carcinoma.
An association between ODC induction and tumour promotion also
appears to operate in the colon. Ball has found a significant rise
in ODC activity in rodent colon after dimethyl hydrazine
administration.190 Takano191 and Rozhin192 have both reported early and 
significant increases in ODC activity following intrarectal 
instillation of N-methyl-N-nitro-N-nitrosoguanidine (MMNG) or tumour- 
promoting bile salts.
Bile salts also result in stimulation of ODC activity in
gastric mucosa.193 The intrarectal administration of unsaturated 
fatty acids (also believed to be tumour promoters in the colon) 
resulted in a 23-fold to 49-fold increase in ODC activity.194
Luk, et al.,195 observed that the azoxymethane-treated rat model 
of colonic carcinogenesis appears to be a multi-step process with ODC 
activity increased four times higher than normal mucosa.
The importance of ODC induction in the causal relationship to 
the carcinogenic process in the colon has been underlined by
observations using the irreversible inhibitor of ODC - DFMO. The 
concomitant administration of DFMO will markedly reduce the incidence 
of colon tumours in mice treated with dimethyl hydrazine196 or rats 
given azoxymethane.197 DFMO has also been shown to decrease growth of 
Wilms tumour, renal adenocarcinoma198 and mammary tumours.199
Mouse colon cancer cell line doubling time is increased both in
vitro and in vivo by DFMO.200 The activity of ODC in the colon does
not reflect proliferative rate. Ornithine decarboxylase activity is 
highest in the region of the villous tip and lowest in the crypts, 
although the crypt is the site of cell division. AdoMetDC activity, 
however, shows the opposite pattern.201 Tutton and Barkla202 found 
cell proliferation in primary colon tumours to be substantially 
suppressed by a single dose of DFMO. A much larger dose was required 
to inhibit normal crypt epithelium in small and large intestines,
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however cell proliferation in normal mucosa is known to be faster 
than in tumours, which characteristically are slow growing.202,203 
They purported that altered regulation of ODC is present in the 
tumour tissue and that cell proliferation is more ODC-dependent in 
neoplasia.
In general, the rapid increase of ODC activity is paralleled by 
an increase in activity of AdoMetDC,although the response is slower 
and less marked.119 Porter et al.,189 found AdoMetDC activity to be 
high in both colorectal carcinomas and polyps compared to normal 
mucosa, the mean value for polys being lower than for carcinomas.
1.11 Aims
The aims of this work were several-fold.
1. To map the chromosomal locus of the ODC gene.
2. To map the chromosomal locus of the AdoMetDC gene.
3. To investigate ODC gene polymorphism in tumours.
4. To study ODC mRNA expression in colorectal neoplasia.
5. To correlate mRNA expression with ODC activity in the same
sample in order to determine methods of ODC regulation in 
colorectal neoplasia.
6. To compare ODC mRNA expression in colorectal neoplasia with
other solid tumours.
7. To determine if ODC and AdoMetDC gene amplification and/or gene
rearrangement occurs in colorectal neoplasia and other solid
*■ tumours.
8. To compare ODC mRNA expression with expression of other genes
known to be altered in colon neoplasia, e.g., IGF-.2
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2. MATERIALS AND METHODS
2.1 Gene Mapping
2.1.1 Somatic Cell Hybridisation
The development of recombinant DNA technology and the use 
of restriction endonucleases (enzymes derived from bacteria 
which cut DNA at specific nucleotide recognition sites) has 
resulted in a logarithmic rise in the number of genes which can 
be mapped.
The technique of somatic cell hybrid analysis is based on 
the use of cytogenetics, enzyme marker and recombinant DNA 
technology.102,204,205 A summary of mapping by somatic cell 
hybrid methodology is given in Figure 4. Mouse and human cells 
are fused using polyethylene glycol. As cells are grown in 
culture, the entire mouse genome is retained, however, certain 
human chromosomes are lost. On the same passage, cells are 
removed and: 1) DNA isolated; 2) homogenised for analysis on 
starch gel electrophoresis using known enzyme markers - the 
chromosomal location of which is already known; and, 3) 
karyotyped to determine which human chromosomes can be 
recognised. The somatic cell hybrid DNA is digested with 
restriction endonuclease, separated by electrophoresis in 
agarose gel and transferred to filters by the Southern 
technique104 for hybridisation with the DNA probe to be mapped. 
The segregation of human-specific bands on the Southern blots 
is correlated with the results of histochemical staining and 
karyotyping to assign the gene locus.
A panel of human-mouse hybrids is obtained so that the 
full human chromosome complement is obtained.
A test blot is usually run where DNA is digested with 
several different restriction endonuclease, and the enzyme 
resulting in good separation between human and mouse bands for 
that gene, is chosen for subsequent mapping experiments.
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Figure 4
Happino of Cloned Genes in Huroan-roouse Somatic 
Cell Hybrids bv Southern Blotting 
Clones of cell hybrids containing certain human chromosomes are cultured and 
harvested. From the same passage cells are used to prepare DNA, cell-free 
homogenates, and for karyotyping. Human enzyme markers previously assigned 
to human chromosomes are assayed by histochemical staining. Confirmation 
of human chromosome content is provided by karyotyping. DNA from each group 
of cell hybrids is cleaved with restriction endonuclease, giving a unique 
pattern of human and mouse fragments when hybridised to a radiolabelled gene 
after Southern blotting. The segregation of human-specific bands on 
Southern blots is correlated with the results of histochemical staining and 
karyotyping to assign the gene to a chromosomal locus.
The presence of chromosome translocations within the 
hybrids, which can be identified karyotypically, allows 
regional mapping of certain genes.
2.1.2 Happing the ODC Gene
The human-mouse hybrid cell lines where derived from the 
following hybrid sets, the human and mouse parental cells given 
in parenthesis: REW (WI-38 x RAG), WIL (WI-38 x LTP), XER
(GM2859 x RAG), JWR (JoVa x RAG), JSR (JoSt x RAG), 1CL (GM1006 
x LMTK’, ATR (AlTr x RAG), TSL (GM2808 x LMTK"), REX (CaVa x 
RAG), SIR (GM469 X RAG), DUA (DUV x A9),206 GAR (GM806 x RAG),207 
VTL (VT x LMTK'),208 DUM (DUV x RAG), NSL (GM2836 x LMTK'), XOL 
(GM0097 x LMTK'), XTR (GM194 x RAG).
The hybrids had been analysed previously for human 
chromosome content using enzyme markers102 and karyotyping 
techniques.209,210 Cells were examined on the same passage 
through cell culture.
Table 1 gives further details of the chromosomes retained 
in these hybrids.
10 /ig DNA from 31 cell hybrids was digested with the 
restriction endonuclease PstI (Boehringer Mannheim) under the 
conditions described by the manufacturer. These hybrids were 
derived from 13 unrelated human and 4 mouse cell lines. The 
enzyme Hind III was used to digest DNA from 37 cell hybrids 
involving 13 unrelated human and 4 mouse cell lines. 0.1 vol 
sucrose dye marker was added and digested DNA fragments were 
separated by electrophoresis in 0.8% agarose in a Tris acetate 
buffer for 16-24 hours at 33-35v, 40-50 mA. The gels were 
stained with ethidium bromide (10 mg/ml) and photographed to 
confirm complete digestion. Gels were denatured for thirty 
minutes in 0.5 MNaOH and 1.5 M NaCl, then neutralised for 
thirty minutes in 3MNaCl 0.5 M tris pH 7.0. DNA was then 
transferred to zetapor (AMF Cuno) in 20 x SSC overnight by the 
technique described by Southern.104 Filters were pretreated 
with 2 x SSC, baked in a vacuum oven at 80° C for 3-4 hours and
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washed for 1 hour in 0.1 x SSC, 0.5% SDS (sodium 
dodecylsulphate) at 65°C.
Prehybridisation took place at 42#C overnight in 50% 
deionised formamide, 5 x SSC/5 x Denhardt's, 50mM NaP04 pH 6.5,
500 Mg/ml sonicated salmon sperm DNA, and 0.1% SDS.
32The ODC probe was labelled with P by nick translation 
and the blots hybridised for 48 hours at 42* C in a solution 
containing 200 pg/ml sonicated salmon sperm DNA, 50% formamide, 
5 x SSC/5 x Derhardt's, 1 x SSC, 20 mM NaP04 (pH 6.5), 10% 
dextran sulphate, and 0.1% SDS. Filters were washed under low 
stringency conditions (1 x SSC; 0.1% SDS) for 1 hour at 60°C. 
Autoradiographs were obtained after exposure at -70° for 3-5 
days. Blots were then washed under conditions of high 
stringency (0.1 x SSC, 0.1% SDS) at 68#C for 1 hour. After 7- 
14 days at -70°C, autoradiographs were obtained.
(
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Table 1
House-human Cell Hybrids for Happing ODC
Hybrid Human chromosomes retained
ATR-13 1,2,3,4,5,6,7,8,10,12,13,14,15,16,17,18,19
DUA-1CSAZF 7
DUA-3BSAGA 2,7,8,13,14,17
DUA-5BSAGA 3,5,11,14,17,18,21
DUM-13 1,2,3,5,6,7,10,11,12,14,16,17,18,19,20,21,22
GAR 1 3,5,8,10,12,14,15,16,20,X
ICL-15 8,12,17,20,21
JSR-2 3,4,7,13,14,X
JSR-14 2,3,4,5,6,12,13,17,20,21,X
JSR-17S 1,2,3,5,8,9,10,11,12,13,14,15,16,17,18,20,21,22
JWR-22H 4,6,7,10,11,12,13,14,15,17,18,20,21
NSL-5 1,8,10,12,14,16,18,20
NSL-16 3,4,5,7,8,10,12,14,15,16,17,18,20,21
NSL-9 5,8,10,12,13,14,15,16,17,20,21,22
REW-7 1,2,3,4,5,6,7,8,10,11,12,13,14,15,17,18,19,20,21,22,X
REW-10 1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,X
REX-llBSAgB 3,10,14,15,18
REX-11BSHF 3,10,14,18
REX-26 1,2,3,4,7,8,8,10,11,12,14,15,16,17,18,19,21
REX57BSHB 14,17,21
SIR 8 1,2,3,4,5,7,8,9,10,11,12,13,14,15,16,17,18,21,22,X
SIR-11 7,13,21,22,X
TSL-1 3,4,9,10,11,13,14,16,17,18,20,21
TSL-2 2,5,6,10,12,18,20,21,X
VTL-6 2,6,7,8,10,11,15,17,19,20,21,22
VTL-7 11,14,17,19,20,21,22
VTL-17 5,7,10,11,13,14,17,20,21
VTL-8 13,15,17,20,21,22
WIL-1 8,12,14,17,18,21,X
WIL-2 8,12,15,17,21,X
WIL-5 4,8,10,17,18,21,X
WIL-6 2,4,5,6,7,,8,10,11,14,17,18,20,21,X
WIL-7 2,3,5,6,8,10,11,13,14,17,18,21,X
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Table 1 (continued)
House-human Cell Hybrids for Happing ODC
WIL-8X 3,4,5,7,8,10,11,12,14,17,18,19,20,21,X
WIL-8Y 3,6,7,8,10,11,14,15,16,17,18,19,20,21,22,X
WIL-14 2,7,8,10,14,15,17,X
WIL-13 3,5,17,18,21,22
WIL-2CSAZ 8,10,12,17,21
XER-11 1,3,4,5,6,7,8,9,10,12,15,16,17,18,19,20,21,22
X0L-6 5,6,7,10,11,12,14,17,19,20,22
X0L-9 2,3,4,6,12,15,17,18,19,21,22,X
XTR-22 2,4,5,6,8,10,11,15,18,19,20,21,22,X
XTR-3BSAgB 9,12,20,21
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2.1.3 Mapping the AdoMetDC Gene by Somatic Cell Hybrid
Techniques
DNA was obtained from somatic cell hybrids. DNA from 38 
somatic cell hybrids involving 14 unrelated human cell lines 
and four mouse lines was digested with the restriction 
endonuclease PstI (see Table 2). 10 jug of each sample was
digested at 37*C for three hours according to the 
manufacturer's instructions (Boehringer-Mannheim). The 
reaction was stopped by heating to 65°C for 10 minutes. 0.1 
vol sucrose dye marker was added and the samples loaded on a 
gel. Separation, transfer, baking, pretreatment and 
hybridisation was as described for ODC mapping. The filters 
were rinsed briefly in 2 x SSC, 0.1% SDS at room temperature, 
then washed individually three times for 20 minutes in 0.1 x 
SSC, 0.1% SDS at 50°C. Dried filters were exposed to Kodak XAR 
5 X-ray film with an intensifying screen for 3-10 days.
The AdoMetDC probe used in these experiments was randomly 
primed.
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Table 2
House-human Cell Hybrids for Happing AdoMetDC
Hybrid Human Chromosomes Retained
ATR-13 1,2,3,4,5,6,7,8,10,12,13,14,15,16,17,18,19
DUA-3BSAGA 2,7,8,13,14,17
DUA-5BSAGA 3,5,11,14,17,18,21
DUM13 1,2,3,5,6,7,10,11,12,14,16,17,18,19,20,21,22
GAR 1 3,5,8,10,12,14,15,16,20,X
ICL 15 8,12,17,20,21
JSR 14 2,3,4,5,12,14,17,18,20,21
JSR17-S 1,2,3,5,8,9,10,11,12,13,14,15,16,17,18,20,21,22
JWR-22H 4,6,7,10,11,12,13,14,15,17,18,20,21
JWR 26C 2,3,4,5,6,7,9,10,11,12,14,15,16,17,18,20,21,X
NSL-5 1,8,10,12,14,16,18,20
NSL-9 5,8,10,12,13,14,15,16,17,20,21,22
NSL-16 3,4,5,7,8,10,12,15,16,17,18,20,21
REW-5 1,2,3,4,5,6,7,8,10,11,12,13,14,15,17,18,19,21,22,X
REW 11 4,7,11,12,13,16,20,21,22,X
REX-llBSAgB 3,10,14,15,18
REX-11BSHF 3,10,14,18
REX26 1,2,3,4,7,8,9,10,11,12,14,15,16,17,18,19,21
SIR-8 1,2,3,4,5,7,8,9,10,11,12,13,14,15,16,17,18,21,22,X
SIR 11 2,9,13,21,X
TSL-1 3,4,9,10,11,13,14,16,17,18,20,21
TSL-2 2,5,6,10,12,18,20,21,X
VTL-6 2,6,7,8,10,11,15,17,19,20,21,22
VTL-7 11,14,17,19,20,21,22
VTL-8 13,15,17,20,21,22
VTL-17 5,7,10,11,13,14,17,20,21
WIL 1 8,12,14,17,18,21,X
WIL-2CSAZ 8,10,12,17,21
WIL 5 4,8,10,17,18,21,X
WIL 6 2,4,5,6,7,8,10,11,14,17,19,20,21,X
WIL 7 2,3,5,6,8,10,11,13,14,17,18,21,X
WIL 8X 3,4,5,7,8,10,11,12,14,17,18,19,20,21,X
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Table 2 (continued)
House-human Cell Hybrids for Mapping AdoMetDC
WIL 8Y 6,7,8,10,11,14,17,18,20,21,X
WIL 14 1,3,5,7,8,10,12,14,15,17,X
XER-7 1,2,3,4,5,6,7,8,9,10,12,13,14,15,18,19,X
XER 11 1,3,4,5,6,7,8,9,10,12,15,16,17,18,19,20,21,22
XTR-3BSAgH 1,3,4,5,9,10,12,20,21
XTR 22 2,4,5,6,8,10,11,15,18,19,20,21,22,X
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2.1.4 Mapping the ODC Gene by In Situ Hybridisation
The method of in situ hybridisation combines molecular 
techniques with high resolution chromosome banding. The method 
used in Dr. Shows' laboratory combines two modifications of the 
technique by Harper and Saunders.211 Longer prometaphase 
chromosomes are obtained using bromodeoxyuridine as a cell- 
synchronizing agent, and a Hoechst 33258/Giemsa chromosome 
staining method results in high-resolution chromosome 
banding.212
2.2 DNA Extraction (Cell si
Approximately 108 cells were removed from plastic flasks by 
trypsinisation and washed several times with serum-free medium. DNA 
was extracted as described in Naylor, et al.213
2.3 Experiments on ODC DNA Polymorphism in Human Blood Samples
Samples of whole blood were obtained from Red Cross volunteers. 
White blood cells were isolated from heparinised blood using the 
dextran sedimentation method described by Skoog and Beck. 214 3%
dextran, MW 228,000, pH 7.3, was added 2:1 to normal blood for a 
total volume of 5 ml. Red cell sedimentation occurred in 18-20 min. 
The overlying supernatant plasma-dextran suspension of leukocytes and 
platelets was removed without disturbing the red cells. Leukocytes 
were selectively sedimented by centrifuging the supernatant at 800- 
1200 RPM for 7-10 min. The resulting leukocyte pellet was frozen in 
liquid nitrogen for later DNA extraction, or used immediately.
2.4 Study of ODC Expression in Tumours
2.4.1 Tissue Procurement
Surgical samples were obtained with the help of the 
Department of Surgical Oncology Service of Roswell Park Cancer 
Institute. Patients gave signed consent prior to surgery that
37
their operative specimens may be used for research within the 
Institute. Shortly after resection, the samples were taken to 
the Pathology Department where a staff pathologist dissected 
samples of tumour and adjacent normal mucosa. In the case of 
colon, rectum, and stomach, mucosa was dissected from 
submucosa, the sample being taken from grossly normal tissue 
approximately 5 cm distant from the neoplasm. Tissue was 
frozen in liquid nitrogen and stored at -70#C for later 
extraction of DNA and RNA.
2.4.2 RNA Extraction
Tissue samples were removed from -70°C and placed in 
liquid nitrogen. A portion equivalent to 0.5-1 cm3 was 
removed, wrapped in clear kitchen wrap and pulverised into 
small fragments. Fragments were added to 15 ml 4M guanidine 
isothiocyanate and homogenised using a Polytron. After 
filtering with sterile gauze, the volume was made up to 15 ml 
and 3 g ultrapure caesium chloride added and dissolved. The 
mixture was layered onto a 3.5 ml 5.7 M cushion of calcium 
chloride in a SW 41 polyallomer tube.215 Specimens were 
centrifuged in a Beckman ultracentrifuge at 30,000 rpm at 20°C 
for 18 hours. The supernatent was removed with a pipette and 
the RNA pellet dissolved in 1 ml 10 mM Tris pH 7.4, 5 mM EDTA, 
1% SDS. The RNA solution was decanted into a falcon tube, the 
SW 41 tube rinsed and the rinse solution pooled with the RNA 
solution. Extraction was performed with an equal volume of 4:1 
chioroform:butanol. Phases were separated by spinning for 10 
minutes at 2000 rpm. The top phase was removed and the organic 
phase reextracted with an equal volume of the Tris/EDTA/SDS 
buffer. To the RNA solution was added 0.1 vol Na acetate pH
5.2 and 2.2 vol 100% ethanol. Afer 2-12 hours, at -20#C the 
solution was centrifuged at 9500 RPM for 15 minutes at 4 #C. 
The pellet was dissolved in filtered water and reprecipitated 
in sodium acetate and ethanol as above. The final RNA pellet 
was dissolved in filtered water and quantified by absorbance.
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2.4.3 Dot Blots
Dot blot Northern analysis was performed according to the 
procedure of Kafatos, et al.216 Briefly, this involved 
incubating the RNA samples with SSC and formaldehyde, then 
spotting 10 pg of denatured total RNA onto zetabind (AMF Cuno) 
using a Schleicher and Schuell apparatus.
2.4.4 Northern Analysis
10 pg RNA was ethanol precipitated using 0.1 vol 3.0 M 
sodium acetate pH 5.2 and 2.2 vol cold 100% ethanol. The 
pellet was resuspended in 3.7 pi 0.2 micron filtered water to 
which was added 2.7 pi deionized glyoxal (40%),217 8 pi 
spectrograde DMS0, 1.6 pi 0.1 M NA phosphate pH 6.8. Samples 
were incubated at 50°C for 60 minutes. After cooling to room 
temperature, 4 pi of RNA loading buffer was added to each 
sample (50% glycerol, 0.01 M Na phosphate, pH 7, and 0.4% 
bromophenol blue). Samples were loaded onto a 1.2% agarose gel 
in 0.01 M Na phosphate, pH 6.8, and run at 95 volts for four 
hours with the buffer recirculated from cathode to anode to 
maintain equal pH. RNA was transferred overnight onto zetabind 
and dried at room temperature. Shortwave ultraviolet light for 
three minutes exposure crosslinked the RNA to zetabind and 
allowed localisation of the 18S and 28S bands.
Northern blots were prehybridised for five minutes at 65#C
in 1%.BSA, Na2 HPOyNaH;, P04 0.5 mM, Na2 EDTA 1 mM, 7% SDS, pH
7.0. Radiolabelled probe was added, total counts being 10 x 
106 cpm/ml and blots were hybridised overnight at 65#C in the 
same solution used for prehybridisation.
The blots were removed and washed twice in buffer A (see 
Appendix) at 65°C for 10 minutes each. Blots were washed three 
times in buffer B at 65°C, 10 minutes each. After a very brief 
wash in ddH20, blots were dried and exposed to film.
To quantify the amount of ODC expression, Northern blots
were also hybridised with the cDNA probe for the enzyme triose 
phosphate isomerase (TPI). TPI is a housekeeping enzyme
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involved in glycolysis, gluconeogenesis and the pentose
phosphate shunt. Swartout, et al.,218 have also used TPI as an
internal control for experiments on haematologic malignancies.
2.5 Measurement of ODC Activity
ODC activity was measured using the technique of Seely and 
Pegg.219
2.6 Experiments on ODC and AdoMetDC DNA Gene Amplification and
Deletion in Colorectal Neoplasia and Other Tumours
2.6.1 DNA Extraction (Tissue)
0.5 g of frozen tissue was thawed and minced into small 
pieces with a scalpel. The sample was homogenised using a 
Dounce apparatus on ice in 10 mM Tris-HCl, pH 8.0 10 mM EDTA, 
150 mM NaCl. The homogenate was decanted into a Falcon tube 
and the homogeniser rinsed with fresh buffer which was pooled 
with the homogenate. The volume was made up to 10 ml and 
Proteinase K added to a concentration of 1 mg/ml. SDS was 
added to a final concentration of 1% and the tubes incubated 
overnight at 37°C. Extraction was performed once with an equal 
volume of phenol (10,000 RPM 10 min.) and once with 
chloroform:iso amyl alcohol (24:1). The aqueous phase was 
decanted with a large bore pipette and to this added 1/10 vol 
3M sodium acetate and 1 vol isopropanol. After inverting the 
tube several times DNA floated to the surface where it could be 
collected with a hooked pipette. DNA was rinsed in 70% ethanol 
and dissolved in 1-2 ml of 10 M Tris-HCl, pH 8.0, 10 mM EDTA. 
Quantitation was achieved by reading absorbance at A-260.
2.6.2 Southern Analysis
10 ng DNA was digested with restriction endonucleases run 
on 0.8% agarose in tris acetate buffer and transferred to 
zetapor by the Southern technique. Prehybridisation and
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hybridisation were as described for somatic cell mapping. 
Filters were rinsed briefly at room temperature in 2 x SSC 0.1% 
SDS then washed at 50° in 0.1 x SSC 0.1 % SDS three times. 
Autoradiographs were obtained after two to seven days at -70*.
2.7 Probes and Labelling Methods Used
2.7.1 ODC
The human ODC cDNA clone (pODC 10/2H) was a kind gift from 
0. Janne. The clone is 1,825 nucleotides long, with an open 
reading frame of 1,383 nucleotides and is inserted into the 
fcoRI site of pBR 322.
2.7.2 AdoMetDC
The rat cDNA cloned by Pegg, et al.,136 was used in the 
experiments. The 172 bp EcoRl fragment is located 
approximately 370 bp from the 5' end. Significant homology is 
present to the bovine AdoMetDC sequence reported by Mach, et 
al.135
2.7.3 IGF-2
The IGF-2 probe contains a 1046-base pair insert with an 
open reading frame of 790 nucleotides coding for the 180 amino 
acid precursor for IGF-2.86
2.7.4 TPI
The cDNA clone TPI-5a was a kind gift of L. Maquat.220,221 
The clone comprises the last two nucleotides of the translation 
initiation coding region, the entire 744 - nucleotide coding 
region and the 448 nucleotide 3' untranslated region.
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2.7.5 Random Priming
Random priming was used to label linear DNA probes. The
32following were combined - P dATP 200 pCi (after drying in 
dessicator) DNA probe 200 ng, BSA (10 mg/ml) 1 /tl, Hexamer 2.5 
p 1, buffer 2.5 x (10 /il) Klenow 2 /il, H20 to 25 /il. The 
reaction was left overnight and the probe separated on a 
Sephadex column and frozen.
2.7.6 Nick Translation
DNAse I (5 /il) was activated by mixing with 45 /il 
activation buffer and set on ice for two hours. The following 
were combined: 10 x Nick translation buffer 10 /il, BSA (1 
mg/ml) 5 ftl, 1/10 dATP-dGTP 9 /il, 0.5 fig probe DNA, 32P dCTP 
90 pmoles, P dTTP 90 pmoles, water to 95 /tl. DNASE I was 
diluted 5 /il in 495 /il and 1 /il of the second dilution added to 
the mixture. After incubation at 15°C for 10 minutes, 4 /il of 
E. coli polymerase I was added. Incubation continued at 15° C 
and time points taken until an adequate number of counts 
obtained. The reaction was stopped with 0.25 M EDTA buffer and 
the sample frozen.
The labelled probe was run through a 650 Sephadex column 
to remove unbound nucleotide and the probe frozen again for 
later use. 5 x 106 counts per blot were used for hybrid­
isation.
2.8 Statistical Analysis
Nonparametric statistics were calculated to avoid any 
assumption that the data had a Gaussian distribution. Computations 
were made with SPSS (Statistical Package for the Social Sciences). 
Levels of RNA and activity were compared among groups based on Dukes 
stage, tumour primary site, and degree of differentiation using a 
Mann-Whitney test. Matched pairs of tumour and adjacent normal 
mucosa from the same patient were assessed for correlation with a 
Spearman rank-order test and for equality of ODC level with the 
Wilcoxon Matched Pairs test.
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3. RESULTS
3.1 Happing the ODC Gene
3.1.1 Somatic Cell Hybrids !v
The chromosomal assignment of ODC was determined by
correlating the presence or absence of specific human 
chromosomes in a panel of human-mouse somatic cell hybrids with 
ODC sequences in the DNA isolated from these hybrid cell 
lines. The human ODC DNA probe (pODC 10/2H) hybridised to six 
Pstl fragments of human cell line DNA. These fragments 
measured 9.9, 8.4, 5.5, 4.6, 2.8, and 2.1 kb in length (See 
Figure 5).
Under conditions of high stringency, the 9.9 kb band and
2.1 kb band became less prominent (Figure 6). In cell hybrids,
these bands in addition to the 8.4 kb and 4.6 kb bands cannot 
be scored easily due to either overlapping mouse bands or
faintness of the signal. Lanes 1, 3, and 5 are positive for 
the 2.8 kb band; lane 3 positive for the 5.5 kb band; and lanes 
1 and 5 contain hybrids positive for the 8.4 kb band. Analysis 
of 31 mouse-human cell lines and DNA from unrelated individuals 
demonstrated that the 8.4 and 5.5 kb bands were alleles at the 
same locus, and these two bands were counted together for 
scoring purposes.
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Figure 5
PstI Digest of Human-mouse Hybrid DNA Hybridised 
With p ODC 10/2H - Low Stringency
Southern hybridisation of cDNA probe PODC 10/2H to P s tI digests of DNA from 
human (H), mouse (M), and somatic cell hybrids (lanes 1-5). Low stringency 
wash conditions; lane 3 is positive for the 5.5 kb band; lanes 1, 3 and 5 
are positive for the 2.8 kb band; and lanes 1 and 5 are very weakly positive 
for the 8.4 kb band and are often difficult to score in cell hybrids. 
Lengths of DNA bands are indicated in kb on the right of the figure.
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Figure 6
PstI Digest of Human-mouse Hybrid DNA Hybridised 
With p ODC 10/2H - High Stringency
Same blot as Figure 5 but under high stringency conditions: the 9.9 and 2.1 
kb bands become less prominent.
As shown in Table 3, the 8.4 and/or 5.5 kb bands segregate 
together with the 2.8 kb band (only cell hybrids were included that 
could unequivocally be scored for these 3 bands). These three bands 
were distributed in cell hybrids that without exception retained 
human chromosome 2. All other human chromosomes segregated 
independently of the three bands. Therefore, sequences for these 
three bands are encoded on human chromosome 2.
Regarding the 9.9 kb band, experiments using the human-mouse 
hybrid DUA-1CSAZF, which has retained only human chromosome 7, reveal 
that the 9.9 kb band on Pstl digests is present in this hybrid 
(Figure 7) and therefore this band maps to human chromosome 7 
(detailed mapping of ODC sequences to chromosome 7 is described 
below).
3.1.2 In Situ Hybridisation
In situ hybridisation was effective in localising the 
sequences on to a specific site on chromosome 2 (Figures 8 and 
9). Of the 1,987 metaphase chromosome sets examined, 361 
attached silver grains were seen with 58 grains (16.1%) 
touching chromosome 2. Thirty-one percent of the grains on two 
were located at 2p25. Fourteen grains were distributed on 
chromosome 7 but never above background levels at any site. No 
significant distribution of grains was observed on any human 
chromosome except chromosome 2 at p25. This locus was termed 
0DC1.
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Table 3 
(see following two pages)
Legend Table 3
Distribution of the human ODC gene in DNA from cell hybrids digested with 
PstI. A "t" in the table indicates a chromosome translocation for a 
particular chromosome, but no intact chromosome is present. Concordant 
hybrids have either retained or lost the human ODC bands together with a 
specific human chromosome. Discordant hybrids have either retained the 
gene, but not a specific chromosome, or the reverse. Percentage of 
discordancy indicates the degree of discordant segregation for a marker and 
a chromosome. A 0% discordancy is the basis for chromosome assignment.
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Figure 7
PstI Digest Showing Hybrid DUA-ICSAZF Retaining Chromosome 7 Only 
Southern analysis of DNA digested with P s t l . Lanes: 1-6 human controls, 
lane 7: human-mouse hybrid DUA-ICSAZF, which has retained only human 
chromosome 7 and lane M, mouse control. Lane 7 is positive only for the 9.9 
kb band which, therefore, maps to human chromosome 7.
O D C
Figure 8
In Situ Hybridisation With d ODC 10/2H
Distribution of silver grains localising ODC on chromosome 2 from 198 
metaphases. There were 56 metaphase cells with grains on chromosome 2 
(29.3%). Thirty-one percent (18/58) of the grains on chromosome 2 are 
located at 2p25. A representative metaphase chromosome 2 is shown with 
labelling of 2p25 (arrow). There was no significant accumulation of silver 
grains above background at any other chromosomal site, including chromosome
7.
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Chromosomes
Figure 9
Idiogram Showing the Grain Distribution in 198 
Metaphases for the Probe d ODC 10/2H 
The X axis represents the chromosomes and their elective size proportion, 
the Y axis, the number of grains. There is a highly significant amount of 
labelling at 2p25 in comparison to nonspecific background for the other 
chromosomes.
3.1.3 Chromosome 7 ODC Segment
The DNA of 35 human-mouse hybrids was digested with
Hind III. Under conditions of low stringency, two fragments of 
human DNA hybridised to the ODC probe measuring 5.5 and 4.0 kb, 
respectively (Figure 10). The 4.0 kb band is positive in lane 
1 and the 5.5 kb band is positive in lanes 1, 2 and 3. Under 
more stringent conditions, the 4.0 kb band is less prominent, 
and the 5.5 kb band is seen more clearly (Figure 11).
Table 4 reveals that the 5.5 kb band is located on
chromosome 2, and the 4.0 kb band on chromosome 7. The hybrid
JSR-17S with the translocation 7/9: 7pter-*7q22:9q23->9pter
localised the 4.0 kb band to the q22->qter region of 7. The 
hybrid VTL-7, which is negative for the 4.0 band, has a 
deletion on 7 and has retained only the 7pter-*7q31 region. 
These results would indicate a further localisation of the 4.0 
kb sequence to the 7q31-+7qter region of 7. This locus will be 
termed 0DC2.
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Figure 10
Hindlll Digest of Human-mouse Hybrid DNA Hybridised 
With dODC 10/2H - Low Stringency 
Southern hybridisation of cDNA probe pODC 10/2H to H i n d l l l  digests of human 
(H), mouse (M), and somatic cell hybrid DNA (lanes 1-4) under low stringency 
wash conditions. Lane 1 is positive for the 4.0 kb band, and lanes 1, 2, 
and 3 are positive for the 5.5 kb band.
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Figure 11
H i n d l l l  Digest of Human-mouse Hybrid DNA Hybridised 
With pODC 10/2H - High Stringency 
Same blot as Figure 10, under conditions of high stringency. The 5.5 kb 
band is positive in lanes 1, 2, and 3 and maps to chromosome 2. The 4.0 kb 
band, positive in lane 1, though seen less clearly under these conditions, 
maps to chromosome 7.
Table 4
(see following three pages)
Legend Table 4
Distribution of human ODC sequences in cell hybrids digested with Hindlll, 
The 5.5 kb band mapped to chromosome 2: the 4.0 kb band mapped to chromosome 
7. Cell hybrids JSR-17S and VTL-7, retaining different regions of 
chromosome 7, localise the 4.0 kb band to the 7q31-qter region of chromosome 
7.
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3.2 Happing the AdoMetDC Gene
The chromosomal assignment of AdoMetDC was determined by 
correlating the presence or absence of specific human chromosomes in 
a panel of human-mouse somatic cell hybrids with AdoMetDC sequences 
in the DNA isolated from these hybrid cell lines.
The rat AdoMetDC probe hybridised to four Pst I fragments of 
human WI-38 fibroblast DNA. The fragments measured 7.2 kb, 5.9 kb,
2.9 kb, and 2.2 kb in length. The probe also hybridised to mouse 
DNA; a restriction fragment length polymorphism was noted between the 
RAG and LMTK" mouse cell lines of BALB/c and C3H origins, respectively 
(Figure 12, lanes 7 and 8).
Figure 12 demonstrates the banding pattern seen in human WI-38 
(lane 9), mouse LTP2a (lane 8), and mouse RAG DNA (lane 7). The 5.9 
and 2.9 kb bands were scored. The 7.2 kb band was not scored because 
of its weak signal and proximity to a faint mouse band. The 2.2 kb 
fragment overlapped with a mouse band and could not be scored. Lanes 
1-6 contain the human-mouse hybrid DNAs. Lanes 1, 2, and 3 are 
positive for the 5.9 kb band and have retained human chromosome 6; 
lanes 4, 5 and 6 have lost human chromosome 6 and are negative for 
the 5.9 kb band. Lanes 1, 3, and 5 are positive for the 2.9 kb band 
and human chromsome X; lanes 2, 4, and 6 have lost the X chromosome
and are negative for the 2.9 kb band.
Table 5 shows that the chromosomal assignment is achieved by 
correlating the presence of the bands which can be scored (5.9 and
2.9 kb) with the presence of human chromosomes known to be retained 
in those hybrids. Percent discordancy indicates the degree of 
discordant segregation for a marker and a chromosome, a 0% 
discordancy being the basis of chromosome assignment. It can be seen 
that the 5.9 kb band (designated AMD1) maps to chromosome 6, and the
2.9 kb band (designated AMD2) maps to the X chromosome.
The sequence on X can be further localised on X by the
following hybrids: ATR-13 (+) which contains a 5:X translocation
retaining Xq22->Xqter. REX-11BSHF (+) and REX-26 (+) also contain the 
same translocated portion of X. XTR-3BSAgH (-) has a 3:X 
translocation in which Xq28-Xqter is present. Thus the sequence maps 
to Xq22-Xq28.
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Figure 12
Distribution of AdoMetDC Gene Sequences in Human-mouse Hybrids 
Distribution of AdoMetDC (AMD) gene sequences in mouse (lanes 7,8), human 
(lane 9) and mouse-human cell hybrids (lanes 1-6). DNA was digested with 
Pst I and hybridised with the rat AdoMetDC cDNA probe. Human DNA fragments 
are seen in lane 9 measuring 7.2, 5.9, 2.9, 2.2 kb. Lanes 1, 2, and 3 
contain DNAs from hybrids which have retained human chromosome 6 and are 
positive for the 5.9 kb band. Lanes 4, 5, and 6 contain hybrids negative 
for the 5.9 kb band and chromosome 6. Lanes 1, 3, and 5 are positive for 
the 2.9 kb band and the X chromosome; whereas lanes 2, 4 and 6 have lost the 
X and are negative for the 2.9 kb band. The 5.9 and 2.9 kb bands segregate 
independently, as is seen in Table 5.
Table 5 
(see following three pages)
Legend Table 5
DNA probe for AdoMetDC (AMD) was hybridised to Southern blots containing 
PstI-digested DNA from the hybrids listed. AMD was determined by scoring 
presence (+) or absence (-) of human bands in the hybrids on the blots. The 
table is compiled from 38 cell hybrids containing 14 unrelated human and 4 
mouse cell lines. Concordant hybrids have either retained or lost AMD 
together with a specific human chromosome. Discordant hybrids have either 
lost the gene but not a specific chromosome, or the reverse. Percent 
discordancy indicates the degree of discordant segregation for a marker and 
a chromosome. A 0% discordance is the basis for chromosome assignment. The 
"t" in the table indicates a chromosome translocation for a particular 
chromosome, but no intact chromosome is present. The hybrids were 
characterised by chromosome analysis and by mapped enzyme markers, and 
partly by mapped DNA probes.
The 5.9 kb band mapped to human chromosome 6. The 2.9 kb band mapped 
to human chromosome X. The hybrids with X translocations: ATR-13 (+) with 
the 5pter->5q22+Xqter, REX-11BSHF (+) and REX-26 (+) with the 22pter-» 
22ql3::Xq22-*Xqter, and XTR-3BSAgH (-) with the 3pter->3q21: :Xq28->Xqter, 
localise the 2.9 kb band to the Xq22-*Xq28 region.
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3.3 Chromosome 2 Restriction Fragment Length Polymorphism of ODC
PstI digests of leukocyte DNA from 40 unrelated individuals 
revealed three consistent banding patterns initially suggested by the 
mapping data (Figure 13). In all individuals, the 9.9 kb band 
(localising to chromosome 7) is present. The 2.8 kb band on 
chromosome 2 is also constant, as is the 2.1 kb band. The 4.6 kb
band which could not be used for scoring purposes is seen very 
faintly. The 8.4 kb and 5.5 kb bands mapping to chromosome 2 show a 
DNA restriction fragment length polymorphism since they segregate 
between individuals as alleles at the same locus. These phenotypes 
constitute at least a two-allele locus with the 5.5 kb homozygote in 
lane 1, the 8.4 kb homozygote in lane 2, and the 8.4/5.5 kb 
heterozygote in lane 3. Of 40 individuals, 3 corresponded to the 5.5 
homozygote, lane 1; 21 corresponded to the 8.4 homozygote, lane 2; 
and 16 corresponded to the 8.4/5.5 heterozygote, lane 3. The allele 
frequencies calculated by the Hardy Weinberg Law are 5.5 (p) = 0.28 
and 8.4 (q) = 0.72.
3.4 Correlation With N-mvc
Since the locus for the oncogene N-myc has been mapped to the 
tip of the short arm of chromosome 2, 2p24," and these experiements 
map ODC to 2p25, an experiment was devised to determine if any 
correlation existed between amplification of N-myc and ODC. Two 
neuroblastoma cell lines were provided by Dr. P. Rothberg, one 
exhibiting amplification of N-myc and one without amplification. The 
DNA was digested with PstI, the fragments separated as described and 
probed with pODC 10/2H. No amplification of either ODC locus was 
seen in either neuroblastoma cell line (data not shown).
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Figure 13 
Polymorphism of ODC Among Humans 
The banding pattern of DNA hybridisation with pODC 10/2H in human samples 
after a PstI digest. Only three patterns are seen in 40 samples examined. 
In all samples, the 9.9 kb band (chromosome 7) and the 4.6, 2.8, and 2.1 
bands remain constant. In lane 1, the 8.4 kb band is absent, representing 
the 5.5 homozygote. Lane 2 depicts the 8.4 homozygote. In lane 3, both 
bands are present, representing the 5.5/8.4 heterozygote phenotype. This 
represents a two-allele ODC locus on human chromosome 2.
3.5 The Site of the Functional Gene for ODC
In an attempt to determine which locus, either on chromosome 2 
or chromosome 7 harboured the functional gene, an experiment was 
devised involving mouse-human hybrids in cell culture.
Glyoxal gel analysis was performed comparing mouse and human 
ODC signals (Figure 14). A slight size difference could be used to 
distinguish mouse and human mRNA signals in cell culture. The hybrid 
DUA-ICSAZF, which has retained only human chromosome 7, was grown to 
70% confluency as were TSL-2 and DUA-6, which contain human 
chromosome 2 but not 7. The RNA was run alongside appropriate human 
and mouse controls in 1.5% agarose. Review of the autoradiographs 
suggested there to be a human signal from the hybrids containing 
chromosome 2, and not from the 7-only hybrid, but this result was not 
conclusive.
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Figure 14
Northern Analysis of ODC Expression in LMTK' House and Human RNA 
Northern analysis of ODC expression for LMTK' mouse (M) versus human (H) 
total RNA. There is a slight size difference between the major mouse band 
(2.1 kb) and the only human band (2.2). A further mouse signal (2.6 kb) is 
seen.
3.6 ODC mRNA Expression in Colorectal Neoplasia
An initial dot blot of ODC expression in colonic tumours and 
paired adjacent mucosa revealed greatly enhanced expression in 
tumours (Figure 15). Further experiments were therefore performed 
using glyoxal gel analysis.
ODC mRNA expression was examined in 18 patients with paired 
samples of sporadic colorectal carcinoma and adjacent, pathologically 
normal mucosa and in four patients with polyps - two of whom had two 
polyps. It was found that the mRNA expression of the housekeeping 
enzyme triosephosphate isomerase (TPI) closely follows the amount of 
28S and 18S RNA loaded into each well, and therefore this uniform 
expression between normal and tumour tissue could be used as an 
internal control by which expression of ODC could be quantitated. 
Figure 16 shows mRNA expression of ODC and TPI in four patients. TPI 
expression remains relatively constant between tumour and normal, 
whereas ODC shows increased expression in all tumours and polyps 
examined. In all samples, the ODC message was of constant size: 2.2 
kb, and only one transcript was seen by Northern analysis.
Of the 18 colorectal tumours, one of which was a local 
recurrence, seven were located in the rectum, six in descending colon 
or sigmoid, two in the transverse, and three in the caecum; 12 were 
moderately-differentiated, three poorly-, and three well- 
differentiated. Six were Stage BI, 3 BII, 5 Cl, and 4 Cl I (Table 
6). Polyps were tubular or villous with mild-to-moderate atypia 
(Table 7).
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Figure 15
Dot Blot Analysis of Three Colorectal Carcinomas Probed With d ODC 10/2H
Dot blot analysis of total RNA isolated from three colon carcinomas (T) and
32corresponding adjacent normal mucosa (A). Hybridisation of P-labeled pODC 
10/2H to 10 /jg total RNA sample.
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Figure 16
Northern Analysis of ODC mRNA Expression in Four Colorectal 
Cancers With Ad.iacent Mucosal Controls 
Northern blot of glyoxal gel analysis of tumour (T) and adjacent normal 
mucosa (A) of four patients with colorectal carcinoma. Lane M represents 
normal mucosa from a patient who did not have colon cancer. The ODC (2.2 
kb) and TPI hybridisation signals are shown. ODC expression is markedly 
increased in tumours, whereas TPI remains relatively constant between tumour 
and adjacent mucosa. The position of 28S and 18S ribosomal bands are shown.
Table 6
Colon Carcinoma Specimens From Which ODC RNA Analysed
Patient Site
Degree of 
Differentiation Stage
CC 10 Sigmoid Moderate BI
11 Sigmoid Well BI
12* Sigmoid Poor CII
14 Sigmoid Poor CII
15 Rectum Moderate Cl
17 Caecum Well BI
22 Rectum Moderate CII
27 Caecum Moderate BI
28 Rectum Moderate Cl
29 Rectum Moderate BI
30 Caecum Poor CII
31 Transverse Moderate Cl
32 Sigmoid Moderate Cl
35 Splenic flexure Moderate BI
36 Rectum Moderate BII
37 Descending Well BII
38 Rectum Moderate BII
41 Rectum Moderate Cl
* = local recurrence
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Table 7
Polyp Samples for Which RNA Analysed for ODC Expression
CP2 Ascending colon
CP3' Caecum
CP3S Ascending colon
FPC5 Rectum
FPC30S Sigmoid
CC36P Sigmoid
Villous with mild atypia 
Villous with mild atypia 
Tubulovillous with mild atypia 
Tubular with moderate atypia 
Tubular with moderate atypia 
Villous with mild atypia
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RNA expression was expressed as an ODC/TPI ratio for tumour and 
adjacent normal tissue. The fold increase of tumour compared to 
adjacent mucosa can therefore be derived. There was a significantly 
higher ODC mRNA expression in primary tumours than in adjacent mucosa 
for each paired sample (p < 0.001 Wilcoxon matched pairs test). This 
is graphically demonstrated in Figures 17 and 18. A similar finding 
was noted for polyps, mRNA expression always being higher than in 
normal tissue. Of 17 colorectal tumour primaries and one local 
recurrence, the fold increase of ODC mRNA expression in tumour 
compared to adjacent mucosa ranged from 1.29 to 12.2 with a median of 
3.42 and mean of 4.19 (± 2.756) and a moderate correlation 
coefficient of .79 (p < 0.001, Spearman correlation) (Figure 19). 
For six polyps, the fold increase ranged from 1.5 to 9.05 with a 
median of 2.8 and mean of 3.2 (± 1.67).
RNA expression and fold increase was examined with respect to 
site of tumour (rectum versus elsewhere in the colon), stage of 
primary tumour (B versus C), and degree of differentation. ODC mRNA 
expression was independent of these parameters, although there was a 
suggestion of a difference for adjacent mucosal RNA, the expression 
being higher in the rectum than the rest of the colon (p = 0.09 Mann 
Whitney) (Figure 20).
3.7 ODC Activity and mRNA Expression
In 15 patients, paired samples from the same patient were 
analysed for both ODC activity and mRNA expression to investigate 
whether a direct correlation was present. Although all samples 
exhibited a significant increase in both ODC mRNA levels and ODC 
activity when compared to adjacent normal tissue (see Figures 18 and 
21), no correlation was found between ODC RNA expression and activity 
within the same tissue samples (Spearman correlation coefficient 
0.068, p = 0.81) (Figure 22).
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Figure 17
Scatteroram Depicting the Relationship of ODC/TPI Ratio in Colorectal 
Primary Tumours Versus Adjacent Normal Tissue 
Scattergram depicting the relationship of ODC/TPI ratio for colorectal 
primary tumours versus adjacent normal mucosa. ODC RNA expression is 
consistently higher in tumour than mucosa (p < 0.001, Wilcoxon matched pairs 
test).
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Figure 18
Comparison of ODC Expression for Cancers. Pol yds, and Adjacent Mucosa 
Graph depicting ODC/TPI ratio for colorectal tumours and polyps with 
corresponding normal adjacent mucosa as control.
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Figure 19
ODC Fold Increase in RNA Expression for Colorectal Tumours 
Graph showing fold increases of ODC RNA expression of colorectal primary 
tumours (0) and one local recurrence (X). Median 3.42, mean 4.19.
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Figure 20
ODC/TPI Ratio for Ad.iacent Normal Mucosa of Rectum Versus Rest of Colon 
ODC/TPI ratio for adjacent normal mucosa from rectum versus rest of colon. 
There is a suggestion of a higher value for rectal mucosa.
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Figure 21
ODC Activity in Colorectal Tumours. Polyps, and Adjacent Mucosa 
Comparison of ODC activity (pmol C02/hr/mg protein) in colorectal tumours 
and adjacent normal mucosa and benign polyps and adjacent normal mucosa. 
Activity data are available for 15 out of 18 tumour and mucosa samples 
depicted in Figure 18 and four out of six polyps and mucosa samples.
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Figure 22
Scattergram Depicting Tumour ODC Activity Versus mRNA Expression 
Scattergram showing tumour ODC activity versus mRNA expression in the same 
sample. 0 = local recurrence, x = primary tumour. No statistical 
correlation is found.
3.8 ODC Expression in Other Tumours Examined by Northern Analysis
RNA was also extracted from three gastric tumours, two 
leiomyosarcomas and two liposarcomas. In all tumour types, a single 
transcript of 2.2 kb was seen (Figure 23), and, again, there was 
elevation of ODC RNA expression in tumour compared to normal tissue 
(normal controls were not available for sarcomas). However, it was 
noted that the ODC/TPI ratio for gastric tumours and adjacent 
controls and for sarcomas was generally lower than for colorectal 
samples (Figure 24), although the number of samples examined was 
small. This is also reflected in the fold increase of tumour RNA 
expression over adjacent tissue, the mean being 1.87 for gastric 
tumours and 4.2 for colorectal tumours (Figure 25).
3.9 ODC DNA Analysis in Colorectal Neoplasia
In all, 18 colorectal carcinomas and seven colorectal polyps 
were examined. The tumour was well-differentiated in one patient, 
moderately-differentiated in 12, and poorly-differentiated in five. 
Site was distributed as follows: rectum seven, sigmoid/descending 
colon four; transverse three, and caecum four. Stage of the primary 
tumour (GITSG) was BI in four patients, BII in five, Cl in six, and 
CII in three (Table 8). Of the seven benign polyps, six were villous 
adenomas with mild-to-moderate atypia and one was recorded as a 
tubular adenoma with atypia (Table 9). Tumour or polyp DNA was run 
alongside matched pathologically normal adjacent mucosa DNA from the 
same patient and from normal controls. No amplification of either 
ODC locus was seen in either carcinoma or polyp with either PstI or 
Hindlll digests after Southern blot analysis (Figure 26).
DNA was also analysed from two samples of leiomyosarcoma, five 
liposarcomas, three infiltrating ductal breast carcinomas, one lung 
carcinoma, and six gastric carcinomas, along with corresponding 
controls - no amplification of the ODC gene was seen.
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Figure 23
Northern Analysis of ODC Expression in Two Gastric Cancers 
Glyoxal gel analysis of ODC RNA expression in gastric tumours from two 
patients (T) and corresponding adjacent mucosa (A). ODC and TPI signals are 
seen. A single ODC transcript, 2.2 kb size, is seen.
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Figure 24
Graph Depicting ODC/TPI Ratio for Colorectal Neoplasia.
Gastric Tumours, and Soft Tissue Sarcomas 
Graph depicting ODC/TPI ratio for colorectal neoplasia and controls, gastric 
tumours and adjacent mucosa and for soft tissue sarcomas. ODC expression 
is generally higher in colon neoplasia compared to gastric cancer and 
sarcomas.
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Figure 25
Fold Increase of Neoplasia Over Mucosa for Colorectal 
Tumours. Pol yds, and Gastric Cancers 
Fold increases of neoplasia over mucosa for colorectal tumours, polyps, and 
gastric carcinomas. Mean fold increase for gastric cancer was 1.87 compared 
to 4.2 for colon tumours.
Table 8
Data on Colorectal Cancer Specimens From Which ODC DNA Analysed
Patient Site
Degree of 
Differentiation Stage
CC 14 Sigmoid Poor CII
15 Rectum Moderate Cl
17 Caecum Well BI
22 Rectum Moderate CII
26 Sigmoid Poor BI
27 Caecum Moderate BI
28 Rectum Moderate Cl
30 Caecum Poor CII
31 Transverse Moderate Cl
32 Sigmoid Moderate Cl
36 Rectum Moderate BII
38 Rectum Moderate BII
39 Splenic flexure Poor BII
41 Rectum Moderate Cl
48 Rectum Moderate BII
49 Transverse Moderate Cl
50 Sigmoid Moderate BI
51 Caecum Poor BII
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Table 9
Data on Polyp Specimens from Which ODC DNA Analysed
Patient Site Type
CP 1 Rectum Villous with mild atypia
CP 2 Ascending colon Villous with mild atypia
CP 3 Caecum Villous with mild atypia
CP 4 Caecum Villous with mild atypia
FPC 5 Rectum Tubular with moderate atypia
CC36P Sigmoid Villous with mild atypia
CC52P Sigmoid Tubular with atypia
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Figure 26
Southern Analysis of Tumour. Polyp, and Ad.iacent Mucosa Probed 
With dODC 10/2H. 10 uq of DNA in Each Lane
Lane 1 CC 36 Rectal carcinoma
Lane 2 CC 36P Sigmoid adenoma from same patient as lane 1
Lane 3 CC 36' Adjacent rectal mucosa from same patient as
Lane 4 CP 3 Caecal polyp
Lane 5 CP 3' Adjacent mucosa from ascending colon
Lane 6 CP 1 Rectal polyp
Lane 7 CP r Adjacent rectal mucosa
Lane 8 CC 39 Carcinoma splenic flexure
Lane 9 CC 39' Adjacent mucosa
Lane 10 MLD - a human control
No amplification of either ODC locus is seen.
In one patient, CC15, there was a difference between tumour and 
mucosal DNA in the chromosome 2 DNA polymorphic band region (Figure 
27). The pathologically normal adjacent mucosa of this patient 
revealed a new rare allele of the polymorphism described above. The 
band for this new allele co-migrates with the original faint 4.6 kb 
band (Figure 27, lane A). This patient is, therefore, designated an 
8.4/4.6 heterozygote at this 1ocus as compared to the 8.4/5.5 
heterozygote in the adjacent control lane and the 8.4 homozygote in 
the far right control lane. The patient's tumour retains the 8.4 kb 
allele in the polymorphic region and a new 6.6 kb band appears, 
suggesting that the chromosomal region encoding the 4.6 kb band found 
in the normal tissue may be altered in the tumour yielding the 6.6 kb 
band. DNA from this tumour and adjacent mucosa samples were also 
digested with Hind III, XbaI, EcoRI, BamHl, and Hinfl, but the 
restriction fragment length polymorphisms and the rearrangement in 
the tumour was not revealed using these restriction enzymes.
Two of the six gastric carcinomas examined also revealed 
polymorphism at the chromosome 2 locus (Figure 28). In lane 3, a 
faint 8.4 kb band is seen in the tumour tissue which is absent in the 
corresponding adjacent mucosa from that patient (lane 4), and in 
lanes 5 and 6, the tumour tissue exhibits the homozygote picture 
whereas the normal mucosa (lane 6) reveals a faint 8.4 kb band 
suggesting the heterozygote. These samples were also digested with 
the enzymes mentioned above but no RFLPs were seen. CC15 and the two 
gastric carcinomas mentioned all showed one transcript measuring 2.2 
kb when examined by RNA analysis.
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Figure 27
Southern Hybridisation of pODC 10/2H to CC 15 (col on cancer number 15) 
Southern hybridisation of cDNA probe pODC 10/2H to P s tI digests of 
colorectal carcinoma CC15 (T) run alongside DNA from normal adjacent mucosa 
(A). A band is seen in the tumour DNA measuring 6.6 kb which is not seen 
in all other patients examined.
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Figure 28
Southern Analysis of Three Gastric Cancer Samples Hybridised With pODC 10/2H 
Southern analysis of DNA digested with Pst I from three patients with gastric 
carcinoma (lanes 1, 3, and 5) and corresponding matched adjacent mucosa as 
controls (lanes 2, 4, 6). In lane 3, a faint 8.4 kb band is seen which is 
absent in lane 4. In lane 6, the adjacent mucosa shows the 8.4 kb band 
suggesting the heterozygote picture but this band is absent in the tumour 
tissue (lane 5).
3.10 AdoMetDC DNA Analysis in Colonic Neoplasia
DNA was obtained from a total of 13 colorectal cancers and 
corresponding adjacent mucosa, and from five benign colonic polyps 
along with adjacent mucosa (Tables 10 and 11). Lymphocyte DNA was 
obtained from a total of nine unrelated volunteers. DNA from 26 
individuals in all was examined.
Tumour or polyp DNA was run on a gel with normal mucosal DNA 
from the same patient. In all 26 cases, the same four human bands 
were found. No polymorphism in PstI digested DNA was seen between 
individuals and no polymorphism noted between tumour or polyp and 
corresponding mucosa. No amplification of either the locus on 6 or 
on X was seen in colorectal cancer or benign colonic polyp DNA 
(Figure 29).
RNA analysis was attempted using the rat AdoMetDC probe; 
however, this was unsuccessful. Although the rat probe appeared 
similar enough to the human for DNA experiments, it did not hybridise 
well enough under the conditions used for RNA analysis.
3.11 Expression of IGF-2 in Colorectal Neoplasia
To determine whether there was any correlation between ODC and 
IGF-2 expression, several samples were also probed with IGF-2 cDNA.
In all, two colonic polyps, four colorectal carcinomas, and 
three gastric carcinomas were examined along with controls. One 
polyp and one colon carcinoma (CC36) revealed very enhanced 
expression, the normal signal being barely detectable (Figure 30). 
No expression was seen in the other samples. Consistently eleveated 
ODC expression was seen in all samples, and thus, no correlation 
existed between IGF-2 and ODC expression.
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Table 10
Colon Carcinoma Samples and Adjacent Normal Nucosa Analysed For AdoMetDC DNA
Patient Site
Degree of 
Differentation Stage
CC14 Sigmoid Poor CII
CC15 Rectum Moderate Cl
CC17 Caecum Well BI
CC22 Rectum Moderate CII
CC26 Sigmoid Poor BI
CC27 Caecum Moderate BI
CC28 Rectum Moderate Cl
CC30 Caecum Poor CII
CC32 Sigmoid Moderate Cl
CC36 Rectum Moderate BII
CC38 Rectum Moderate BII
CC39 Splenic flexure Poor BII
CC41 Rectum Moderate Cl
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Table 11
Colonic Polyp Samples Analysed For AdoMetDC DNA
CP 1 Rectum
CP 2 Ascending colon
CP3’ Caecum
CC36P Sigmoid
FPC5 Rectum
FPC30 Sigmoid
Villous with mild atypia 
Villous with mild atypia 
Villous with mild atypia 
Villous with mild atypia 
Tubular with moderate atypia 
Tubular with moderate atypia
70
1 2  3
* * +  —  7 . 2  kb
mm mm mm  —  5.9
fc-'-ay*8 h- 2 . 9
- 2 . 1
Figure 29
Southern Analysis of Colorectal Neoplasia Samples Probed With AdoMetDC
Southern analysis of tumour, polyp, and adjacent mucosal DNA from the same 
patient digested with Pst I and hybridised with the rat AdoMetDC probe. Lane 
1: tumour CC36; Lane 2: CC36P - Adenomatous polyp; Lane 3: adjacent
mucosa. No amplification or rearrangement is seen.
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Figure 30
Northern Analysis of IGF-2 Transcripts From Colorectal Neoplasia 
Northern analysis of IGF-2 transcripts from colorectal polyp and carcinoma. 
Normal mucosa RNA was in adjacent lanes, but the signal is barely 
detectable. Size of bands in kb given on the left. Elevated expression of 
IGF-2 is seen for one polyp and one carcinoma sample. None of the other 
samples examined (which all showed increased ODC expression) expressed IGF- 
2 .
DISCUSSION
4.1 Happing the ODC Gene
Knowledge of the chromosomal assignment of any gene involved in 
the control of growth and proliferation is a major step in
elucidating possible means of understanding gene control. In this 
case, the ODC and AMD genes are located on different chromosomes.
In 1986, Wingvist, et al.,222 mapped ODC gene sequences to
2pter->p23 and 7cen->qter. In the experiments described in this
thesis, 0DC1 was localised to 2p25 and 0DC2 to 7q31-*qter.
Although there was no evidence of rearrangement of the ODC gene 
in any of the colon neoplasias studied, rearrangement between ODC and 
the switch region of the gamma-1 immunoglobulin gene has been 
reported in mouse myeloma cells.223 Chromosomal translocation 
involving the short arm of chromosome 2 have been described in
various haematologic malignancies.224,225
It is possible that rearrangement accounts for the deregulation 
of ODC in certain tumour types. Thus, it is interesting to know the 
location of ODC in relation to other gene sequences on chromosomes 2 
and 7 which are known to be involved in tumour growth and 
progression.
The 2p25 ODC locus is known to be close to a fragile site 
(2p24.2)226 and to the avian myelocytomatosis related oncogene MVCN, 
formerly called NYMC227 (2p24). A relationship between fragile sites 
and breakpoints of recurring chromosomal abnormalities has been 
hypothesised,94 and certain carcinogens increase the frequency of 
chromosomal breakpoints.
Transforming growth factor a, an autocrine growth factor 
expressed in many solid tumours,228 and in colon cancer cell lines,229 
is also located on the short arm of chromosome 2.230 Glucagon, a 
trophic hormone, is located on 2.231
The proximity of the ODC gene to the ribonucleotide reductase 
gene is especially interesting. Ribonucleotide reductase catalyses 
the first unique rate limiting step in DNA synthesis, both large 
(RRM.,) and small (RRM2) subunits being necessary for activity.232 
Srinivasan, et al.,233 have shown coamplification of the genes for 
ribonucleotide reductase subunit M2 (RRM2) and ODC in hamster cell 
lines resistant to hydroxurea. Tonin, et al.,234 found this
phenomenon in humans plus the amplification of p5-8, a 55,000 dal ton 
protein. In hamsters, all three loci cosegregate with chromosome 7. 
The human gene for RRM2 is found at 2P24-25236 and is therefore 
closely linked with the ODC gene at 2p25.
McClarty, et al.,237 have shown that the RRM2, ODC and p5-8 
genes exist as a single amplicon in hamster cells and that a parallel 
decline in hydroxyurea resistance is accompanied by a decline in copy 
number of all three genes.
It is interesting to speculate that this region may act as a 
multidrug resistance genetic unit, since DFMO resistance leads to 
amplification of ODC in some instances. Whether RRM2 and p5-8 are 
also co-amplified in DFMO resistance has not been reported to date. 
The fact that two genes so involved in DNA synthesis and cell 
proliferation are in such proximity indicates that they may both be 
acted upon by the same regulatory sequences.
The relationship between the RRM2, p5-8 and ODC coamplicon and 
N-myc has been expanded recently in a report by Tonin, et al.238 
Winquist,222 et al., noted that the ODC gene was not coamplified in 
certain neuroblastomas which demonstrated amplified N-myc, confirming 
the finding described in this thesis. Tonin, et al., found, however, 
that coamplification of ODC and N-myc occurred in one of six human 
neuroblastomas. RRM2 and p5-8 were not amplified. Since 
amplification of N-myc is known to correlate with advanced disease 
stage in neuroblastoma," it is possible that coamplification of ODC 
may act as another prognostic indicator in this disease.
The region 7q31->qter in which 0DC2 resides also contains loci 
for cystic fibrosis (7q31), three fragile sites (7q31.2, 7q32.3, 
7q36), hi stones H2A, H2B, H3, H4, multiple drug resistance (7q36), the 
met protooncogene (7q31-q32) and the oncogene INT-1 (7q31-q32). The 
regulatory polypeptides protein kinase type I (pl3-qter) and II (q31- 
qter) and two genes thought to be involved in metastasis-1aminin 
(q31) and TTIM1 (q32-qter), also reside on 7 . 239'240 The expression of 
epidermal growth factor receptor (EGFR), which resides on chromosome 
7, correlates with structural or numerical alterations of the 
chromosome.241 Genes located on 7 appear to be essential for 
metastasis and invasion to occur; EGFR and platelet derived growth 
factor A (PDGFA) have been postulated to be involved.242
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Several new chromosomal rearrangements on chromosome 7 were 
reported by Trent.224 7q translocations were reported for colon 
cancer, breast cancer, and melanoma.
4.2 The Functional Gene for ODC
Having mapped two loci for ODC, the question arises, which of 
these represents the site of the functional gene?
In the mouse, the ornithine decarboxylase gene is represented 
by a family of at least 14 related loci.243 In the human, only two 
loci exist. Since only one size of mRNA is present, this indicates 
that either both loci are functional, producing message of identical 
size, or one locus is functional, the other being a pseudogene.
Our preliminary data comparing ODC mRNA -expression in human- 
mouse hybrids containing human chromosome 2, but not 7, and 
chromosome 7 alone, suggest that one functional gene exists and is 
located at 2p25.
The in situ hybridisation results also indicate that chromosome 
2 may contain the major locus, since there was no hybridization 
signal on chromosome 7. Fowler, et al.,208 found that human-mouse 
cell hybrid methodology detected loci for a-fucosidase on chromosomes 
1 and 2, but in situ revealed only the functional locus on chromosome 
1. In situ methodology therefore may not be as sensitive as the 
hybrid panel method, accounting for the lack of an ODC signal on 
chromosome 7. More stringent conditions may also contribute to the 
difference. In both the PstI and Hind III digests of the human-mouse 
hybrids, the bands on 7 became less promiiient after a highly 
stringent wash.
Alhonen-Hongisto, et al.,244 studying a human myeloma (Sultan) 
cell line resistant to DFMO found the locus on chromosome 2 to be 
amplified, which also suggests that chromosome 2 carries the 
functional gene. Recently, the mouse ODC functional gene has been 
mapped to chromosome 12 . 245 The other loci are thought to be 
pseudogenes. The assignment to mouse chromosome 12 has been 
confirmed by Berger246 and Villani, et al.247 Mouse chromosome 12 
exhibits considerable homology with human chromosome 2. For example, 
the genes coding for acid phosphatase, propiomelanocortin,
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ribonucleotide reductase M2 and NMYC are all located on mouse 
chromosome 12 and human chromosome 2. This provides further evidence 
that the functional ODC gene is probably located on 2.
The pseudogenes of mouse ODC appear to be very ancient, 
originating about 10 million years ago.248 Pseudogenes were first 
described by Jacq, et al., in 1977.249 They are closely related 
sequences to the functional gene but appear to be inactive. Two 
categories have been identified, the first being genes that have 
retained intervening sequences normally found in the functional gene. 
These are normally located adjacent to the normal functional gene. 
The second category, which occurs much more commonly, are the 
processed pseudogenes. These sequences lack introns suggesting that 
they are derived from processed RNA molecules after reverse 
transcription. Processed pseudogenes are found on different 
chromosomes than their functional homologous sites.250,251
Numerous gene families have been reported in which functional 
and processed pseudogenes reside on different chromosomes, including 
G-3-PD, immunoglobulins, metallothionein II, DHFR, Ki-ras,250,252 
ceruloplasmin251 and aldolase.253
As the sequences for ODC reside on different chromosomes, it is 
likely that the locus on 7 is a processed pseudogene.
Another possibility is that the other sequence on 7 codes for 
a functionally related gene. This is unlikely, however, as no other 
genes have been reported to have significant homology with ODC.
4.3 Mapping the AdoMetDC (AMD1 Gene
Two AMD sequences were localised to chromosomes 6 and X, the 
sequence on X mapping to Xq22-Xq28.
No rearrangement of the AMD loci was seen when samples were 
digested with PstI. It is possible that there may be rearrangement 
which can be detected with other enzymes in colorectal neoplasia and 
that rearrangement may occur in other tumour types, e.g., 
haematologic malignancies.
On chromosome 6 where AMD1 resides, there are genes coding for 
five oncogenes: MYB (q22-q23), PIM (p21), ROSI (q21-q22), SYR (q21), 
and MAS1 (q24-q27).224 There are also four fragile sites and the loci
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PRL (prolactin) (p23-p21) and the oestrogen receptor ESR (q24- 
q27).254,255 Chromosomal abnormalities involving chromosome 6 occur 
mainly in haematologic malignancies but are also seen in melanoma and 
uterine carcinoma.224
The short arm of chromosome 6 is the site of the gene family 
for the major histocompatability complex (HLA).254 Several 
investigators have shown that alterations of the expression of HLA 
genes and thus alterations in HLA phenotype result in changes in the 
metastatic potential of cells.256'259
Chromosome X contains the locus for the oncogene MCF2 at 
Xq27.260 An actively transcribed gene of the raf oncogene group, 
ARAF1 has been localised to Xp21-Xqll.260 It is conceivable that AMD1 
(on chromosome 6) and AMD2 (on chromosome X) may be located near one 
of these growth related genes or within a chromosomal rearrangement 
associated with abnormal growth.
It is possible that either or both of the AMD sequences which 
have been localised may represent functional genes, although since 
two bands could not be scored, a functional gene may be represented 
by one of these unscored bands.
In the rat, a multigene family for AMD exists,261 at least one 
of which is a typical processed pseudogene lacking introns.262
It is possible that both loci for AdoMetDC (AMD1 and AMD2I are 
functional since two forms of AdoMetDC have been reported.170
Two forms of AdoMetDC mRNA have been reported for both rodents 
and humans,261 the smaller mRNA being 2.1 kb and the larger 3.4 kb in 
rats and 3.6 kb in humans.261,263,264 The size difference appears to be 
due to differences in the 3' noncoding end. This may be due to two 
functional loci, or altered transcription of one functional locus.
4.4 Chromosome 2 Restriction Fragment Length Polymorphism of ODC
The data collected from 40 unrelated individuals revealed three 
consistent banding patterns. In all three, the band localising to 
chromosome 7 was present, the allelic diversity occurring at the 
chromosome 2 locus. The phenotypes represented with PstI digests 
were the 5.5 kb homozygote, the 8.4 kb homozygote, and the 8.4/5.5 kb 
heterozygote.
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Both Hickok265 and colleagues and Fitzgerald and Flanagan266 have 
reported RFLPs of the ODC gene seen with PstI digests.
In their experiments, the 5.5 kb homozygote is not identified 
and only two variations are seen. This discrepancy is probably 
accounted for by the fact that the 5.5 kb homozygote exists less 
frequently in the population and is only revealed when a large number 
of patients is examined.
The chromosome 2 polymorphism should be studied further by 
following its inheritance within kindreds.
4.5 ODC mRNA Expression in Colorectal Neoplasia
ODC was found to be consistently elevated in both benign and 
malignant forms of colorectal neoplasia, only one size of message 
being present. Expression was independent of site, stage, and degree 
of differentiation of tumour.
This finding agrees with the results of Kingsnorth, et al.,185 
who found elevated polyamine content in colorectal cancers relative 
to control mucosa. Similarly, elevated ODC enzyme activity in 
neoplasia compared to mucosa has been reported by several authors.186' 
189,192,267-270 KingSnorth and col 1 eagues185 found no correlation between 
polyamine content and tumour site, Dukes stage, histological grade 
and presence of liver metastases. However, LaMuraglia, et al.,187 
noted polyamine content and ODC activity to be higher in well- 
differentiated than poorly-differentiated tumours.
Narisawa, et al.,270 reported a correlation of ODC activity and 
tumour site. They found a statistically significant increase in 
activity in left-sided compared to right-sided tumours. However, 
Porter's lab,267 on the contrary, found the activity of colon 
adenocarcinomas to be slightly higher than rectal adenocarcinomas. 
It has been noted in recent years that the ratio of proximal to 
distal colon cancers has changed. An increased proportion of right­
sided lesions has been reported, leading several authors to suggest 
that proximal cancers have a different biology and pathogenesis.271,272
Porter's study267 revealed a stepwise increase in ODC activity 
from mucosa to polyp to carcinoma. Luk, et al.,188 have also noted
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that ODC activity increased as degree of dysplasia of polyps 
increased.
No clear stepwise progression of increasing expression of ODC 
from mucosa to polyp to cancer was found in this thesis. The mean 
fold increase was slightly higher in carcinoma compared to polyps 
(3.4 vs. 2.8).
Controversy exists concerning the levels of ODC activity in 
normal uninvolved mucosa. Koo, et al.,273 found the ODC activity of 
rectal mucosa of patients with colonic neoplasia to be higher than in 
controls. A similar finding was noted by LaMuraglia and 
colleagues,187 who found that the ODC activity of non involved colonic 
mucosa from tumour bearing specimens was 165% that of the colonic 
mucosa of nonneoplastic disease (mainly diverticulosis). Both 
Moorehead, et al.,274 and Porter, et al.,267 however, found the enzyme 
activity in normal colonic biopsies to be higher than in tumour- 
bearing patients. As Kingsnorth275 points out, these variations may 
be related to variations in technique. The half-life of ODC being 
the shortest of any known enzyme, prompt handling of tissue samples 
is required to prevent degradation.
It is also possible that a gradient of ODC activity and mRNA 
expression exists in the normal colon. There was a suggestion that 
ODC mRNA expression was higher in normal rectal mucosa than in the 
colon, but this did not reach statistical significance.
Such a gradient could be investigated by taking multiple 
samples along the entire length of the colorectum from the same 
patient. It has been suggested that ODC activity of apparently 
uninvolved mucosa is a marker for increased cancer risk. Luk and 
Baylin188 compared the ODC activity in normal-appearing mucosa 
obtained by flexible sigmoidoscopic biopsy to be higher in patients 
with familial polyposis than in normal controls. "At risk" members 
of familial polyposis families also had a higher mucosal ODC activity 
than their spouses who were not at risk.
Narisawa, et al., also noted that the uninvolved mucosa ODC 
activity was elevated in the presence of synchronous neoplasia.270
It has been suggested that a "mucosal field change" exists in 
the colon in patients with colorectal neoplasia, i.e., that the 
entire colon, particularly the area adjacent to the tumour, should be
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regarded as abnormal. This view arose mainly from studies which 
demonstrated increased sialomucin production in noninvolved mucosa 
adjacent to the cancer276 and from the finding of multiple colonic 
neoplasias (synchronous and metachronous) in about 10% of patients.277
In the experiments described in this thesis, adjacent mucosa 
was sampled approximately 5 cm from the area of neoplasia. Lawson, 
et al.,278 compared the activity of ODC in transitional mucosa 
(defined as within 2 cm of the neoplasia) to mucosa at least 10 cm 
distant and found no significant difference. This finding would 
support the use of mucosa 5 cm distant as a suitable control.
4.6 ODC Activity and mRNA Expression: The Regulation of ODC
In general, the regulation of any enzyme's activity can be 
affected by changes in RNA, protein, or both. Increased RNA 
expression can be due to increased transcription rate, increased 
stability of the mRNA, or altered RNA processing. Increased numbers 
of protein molecules may result from increased translatability of 
mRNA, independent of changes in transcription, and prolonged half- 
life of the molecule. Altered activity, when the number of protein 
molecules is constant, can occur due to conformational changes of the 
protein or binding such as phosphorylation.
Elevations in ODC activity occur in response to a number of 
conditions such as addition of trophic hormones and exposure to 
tumour promoters such as TPA.
Early studies using cycloheximide (which inhibits protein 
synthesis) and actinomycin D (which inhibits DNA dependent RNA 
synthesis) demonstrated that both DNA and RNA synthesis caused 
increased ODC activity in regenerating rat liver.279 In some 
instances, increased ODC levels correlated with fluctuations in 
cyclic AMP (cAMP).280
The response of mouse kidney to a single dose of androgen 
results in increased ODC mRNA with the amount of immunoreactive 
protein closely paralleling the changes in amount of mRNA.281 Most of 
the data acquired to date indicates that changes in ODC activity are 
proportional to enzyme protein content, post-translational 
modifications of the protein playing a minor part.282,283 On the other
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hand, prolonged androgen stimulation results in 10- to 50-fold 
accumulation of mRNA but a 200- to 250-fold increase in protein 
content. Thus, decreased protein degradation also plays a role.281
Response to androgen also differs depending on the genetic 
background of the mice, i.e., to which inbred strain they belong.281
Studies with fibroblast cell lines exposed to stimulation 
result in increased ODC mRNA levels, but it is not clear whether 
increased transcription or stabilisation of existing RNA is the main 
mechanism. Katz and Kahana demonstrated increased transcription in 
BALB/c 3T3 mouse fibroblast cells exposed to serum.284 Rose-John, et 
al.,285 however, using mouse Swiss 3T3 cells to which a tumour 
promoter was added, demonstrated increased mRNA due mainly to
prolonged mRNA half-life.
The response of the rat phaeochromocytoma cell line PC12 to 
nerve growth factor (N6F) was studied by Feinstein, et al.286
Increased ODC RNA levels closely paralleled changes in ODC activity 
both in quantity and time-course. One-third of the ODC RNA induction 
was not blocked by cycloheximide treatment, but was fully inhibited 
by actinomysin D. This suggests that changes in ODC mRNA in this 
system are fully dependent on ongoing RNA transcription, not changes 
in stability of RNA.
White, et al.,287 studied ODC expression in bovine lymphocytes 
in response to concanavalin A (Con A). A five-fold greater increase 
in ODC activity compared to ODC mRNA level occurred suggesting 
increased efficiency of translation of ODC mRNA.
mRNA levels in the cell are dependent on mRNA stability. The 
sequence promoting RNA decay has been identified in the 3' noncoding 
region of the eukaryotic gene.288 Stability of c-myc RNA is related 
to the presence of a long poly (A) tail.218
Whether stability of ODC RNA is related to alterations at the
3' end is unknown.
It appears then that increased ODC activity is due to a number 
of different mechanisms and combinations of mechanisms in different 
cell systems including increased transcription, prolonged RNA 
stability, increased translatabality, and increased protein half- 
life.289
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No studies have investigated the mechanisms of ODC regulation 
in solid tumours.
In the present study, ODC mRNA expression was increased a mean 
of four-fold in carcinomas and three-fold in polyps compared to 
normal tissue. Porter, et al.,267 found ODC enzyme activity for 40 
carcinomas to be a mean of approximately eight-fold greater than 
adjacent mucosa and for 18 polyps the activity was increased four­
fold. For the 15 patients for whom ODC activity and mRNA expression 
data were obtained in this thesis, no correlation was found between 
mRNA expression and activity. It is important to note that no undue 
delay occurred in the handling of these tissue samples, which may 
have contributed to degradation of ODC. All samples were placed 
promptly in liquid nitrogen for later activity and RNA analysis.
Thus, the regulation in colon cancer is unlike, for example,
the androgen stimulated kidney in which mRNA levels are paralleled by
• 'V
activity levels.
The generally increased activity compared to expression in 
colon neoplasia indicates that factors in addition to increased 
transcription or extended stability of RNA are in operation. 
Increased translatability of ODC mRNA may occur as described by White 
and colleagues for bovine lymphocytes.287
It is also possible that altered forms of ODC protein may 
occur, which have increased enzyme activity; for example, an altered 
form of ODC having a prolonged half-life has been found in a human 
neuroblastoma cell line.290
O'Brien, Hietala, and co-workers have found two different forms 
of ODC.291'293 The ODC in mouse epidermal papillomas was activated by 
GTP, the ODC of normal epidermis was not. The two forms of ODC also 
differ with respect to heat stability, Km, and molecular weight. 
More recently, O'Brien's group294,295 has found that the GTP-activated 
form of ODC is also present in human colorectal cancers. Hietala, et 
al.,296 have reported a GTP-activatable form of ODC in 13 of 40 
tumours, compared to 3 of 40 mucosa samples. Multiple size forms of 
ODC were found, some of which were activated by GTP. It was noted 
that proximally-sited tumours contained a higher proportion of these 
GTP-activatable forms. The fact that only one ODC message is seen in 
colorectal neoplasia indicates that the altered ODC must have arisen
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from post-translational modifications. Such modifications may 
account for the lack of correlation between mRNA levels and activity 
in colorectal neoplasia.
Control of expression of ODC must be coupled to the 
transmembrane signalling pathways which are activated when a mitogen 
interacts with its receptor on the cell surface. Several signal 
transduction pathways are well-known; namely, the 
phosphotidylinositol/ITPj/DAG/Ca4* system, protein kinase-C, the 
adenylate cyclase/cyclic AMP system, and the GTP binding proteins to 
which family the ras proteins belong. These pathways are summarised 
in the reviews by Arbeit297 and Weinstein.298
Growth factor receptors (GFRs) reside in the cell membrane and 
are composed of an extracellular domain, a transmembrane segment, and 
an intracellular domain having tyrosine kinase activity.
The binding of ligand to the GFR results in a cascade of 
proteins phosphorylated on tyrosine, resulting in the release of 
second messengers into the cell. Phospholipase C is one of the key 
second messengers which becomes phosphorylated in this manner. 
Phospholipase C splits phosphoinositol-bis-phosphate (PIP2) to inosine 
triphosphate (ITP3) and diacyl glycerol (DAG). DAG then activates 
protein kinase C (PKC) in conjunction with calcium released from 
cytoplasmic vesicles by ITP3.
Protein kinase C299 is one of the key messengers within the 
cell. The tumour promotor TPA has structural similarity to DAG and 
can activate PKC in the absence of ITP3 and calcium. PKC undergoes 
a conformational change which results in phosphorylation of a protein 
substrate.298
G proteins are a class of proteins which bind GTP. The 
products of the ras proto-oncogene family are related to G proteins. 
The binding of a ligand to GFR causes alterations in the ras protein 
product which causes subsequent binding of GTP. PLC and PKC are then 
activated and thereby nuclear expression is affected. Mutations of 
the ras proteins occur characteristically at codons 12, 13, or 61, 
which cause continuous activation of PKC. G proteins are also 
important in the ^-adrenergic transduction pathway. The binding of 
a molecule to the /J-adrenergic receptor via a G protein activates 
adenylate cylase, rises cAMP levels and results in increased protein
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kinase A levels, which then produces protein phosphorylation in the 
nucleus.298
It is well-known that the application of TPA to skin results in 
an increase in ODC activity,127,164,165 mediated via protein kinase C.300 
In NIH-3T3 fibroblast cell lines, elevations of-ODC activity and mRNA 
in response to growth-promoting factors occurred by two mechanisms: 
one involving protein kinase C and the other independent of PKC.301
Rose-John, et al.,285 noted that TPA can also affect ODC 
expression by increasing the stability of the mRNA.285 In bovine T 
lymphocytes exposed to mitogens, ODC expression is also mediated via 
PKC.302 Hsieh and Verma,303 studying T24 human bladder cancer cells 
exposed to TPA noted that the ODC increase was proportional to 
increased mRNA activity. No change in mRNA half-life occurred. The 
effect of TPA on transcription was abolished in PKC-deficient cells, 
implying that TPA causes an increase in rate of transcription 
mediated via PKC. The transient induction of ODC mRNA by TPA in rat
hepatoma cells was inhibited by actinomysin D, which again suggests
a
a direct effect on new transcription rather than prolonged half-life 
of mRNA.104
Mustelin and col 1 egues305 have discovered a method of ODC 
activation in T lymphocytes which is independent of PKC. In these 
cells, exposure to mitogens results in increased ODC within one 
minute, reaching a plateau in 5-10 minutes. Such early activation is 
independent of new protein synthesis. Their experiments revealed 
that ODC is bound to phosphotidylinositol at the cell membrane. The 
binding of mitogen to a cell receptor activated PLC, mediated via a 
G protein. The PLC enzyme then activated the phosphotidylinositol - 
ODC complex apparently by cleaving ODC from the diacyl glycerol part 
of the molecule.
Thus, it appears that in both T lymphocytes and nonlymphoid 
cells, PKC dependent and independent pathways exist for the 
regulation of ODC expression.306
Both TPA and bile acids administered intrarectally result in a 
rise in ODC activity.191 Bile acids have been shown to enhance PKC 
activity in colonic mucosa, which may account for their tumour 
promotor effect.307
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Studies on PKC content of colon cancers have revealed a 
decrease in tumours compared to normal mucosa of about three-fold. 
PKC is found in both the cytosolic and membrane compartments of 
cells. In those cancers which contained an admixture of benign 
adenomatous tissue, there was an apparent shift of PKC activity to 
the membrane fraction. It has been proposed that early 
transformation of the mucosa is associated with this translocation of 
PKC activity, and in later stages of the disease, total PKC activity 
is down regulated.308'310
More insight into the regulation of the ODC gene in humans has 
been provided by the cloning and sequencing of the whole length human 
ODC DNA. The pODC 10/2H cDNA used in the experiments in this thesis 
contained 1,825 nucleotides, with an open reading frame of 1,383 
nucleotides, yielding a polypeptide chain of 461 amino acid residues. 
The 5' noncoding sequence was 87 nucleotides long, whereas it was 
determined that the full length of the 5' end should be 335
nucleotides long. The 3' noncoding region comprised 346
nucleotides.265 Fitzgerald and Flanagan266 went on to clone the 
complete length of the human gene, using the pODC 10/2H partial 
length clone. The gene is 8 kb in length and divided into 12 exons. 
Van Steeg, et al.,311 have also reported the full length ODC sequence. 
There is considerable conservation of homology between species as 
would be expected for a gene essential in cell proliferation. Eighty
percent to 90% homology has been reported for mouse, hamster, and rat
ODC genes.133,312'318 The sequence of a rat ODC: pseudogene revealed 
over 80% homology with the cDNA.319
The regulation of eukaryotic genes is influenced by cis-acting 
DNA sequences termed promoters and enhancers.320 The promoter is 
essential for the accurate and efficient initiation of transcription 
and is usually located immediately upstream from the transcription 
initiation site. Enhancers, on the other hand, increase the rate of 
transcription from promoters and act in an orientation-independent 
manner. Typical promoters comprise an AT-rich region termed the TATA 
box and several 8 to 12 base pair elements termed upstream promoter 
elements (UPEs). The TATA box influences accuracy of transcription, 
the UPEs, the rate of transcription. The protein which binds to the
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TATA box, TFIID, and which thus plays a central role in mRNA
synthesis, has recently been identified.321,322
The ODC promoter has been identified in the mouse using a
transient expression assay which assesses chloramphenicol 
acetyl transferase activity (CAT). These studies revealed the
promoter to be located within a region several hundred base pairs 
long 5' to the initiation start site.323
Study of the 5' region of the rat, mouse, and human genes 
reveal conserved transcription elements. The human gene contains a 
TATA box, CAAT box, GC rich region, and a cyclic AMP responsive 
element.311 Fitzgerald and Flanagan266 also noted an AP-2 binding site 
whereas Van Steeg, et al., did not.311 The mouse 5' region also 
contains a cAMP-responsive element,312 three AP-1 binding sites and 
two oestrogen-responsive elements.313 The rat and mouse 5' regions 
have over 90% homology in some areas.313 The rat and mouse genes 
differ in intron length. Nine GC boxes are present in the rat, as 
are two AP-1 binding sites, and one cAMP responsive element.318
The cAMP responsive element is coded by an 8-base palindrome 
5'-TGACGTCA-3'.324
The discovery of AP-1 and AP-2 transcription factors within the 
ODC gene explains the induction of the gene by TPA. Several genes 
which are regulated by phorbol esters contain inducible 
transcriptional enhancers which respond to TPA. The TPA responsive 
element (TRE) binds to the transcription factor AP-1.325,326 Whereas 
AP-1 is activated only by phorbol ester, AP-2 is controlled both by 
the DAG and phorbol ester-stimulated protein kinase C signal 
transduction system and by signalling systems involving cAMP.327
The GC rich areas of the 5' region, for example, exon 1 of the 
mouse gene,314 encode secondary structures which may be involved in 
the regulation of translation of the RNA. Polyamines are known to 
negatively regulate ODC primarily at the level of translation.328'330 
It is possible that polyamines may bind to these GC rich areas and 
stabilise potential secondary structures thereby decreasing 
transl atabil ity.314,317,331
Van Daalen Wetters, et al.,332 found ODC mRNA and enzymatic 
activity to be induced by serum and TPA with similar kinetics even 
when constructs were used which contained only the protein-coding
84
region. Thus, without the flanking sequences, regulation of 
expression and activity can still occur. This suggests that the 
protein coding region may contain regulatory elements which can alter 
the'conversion of transcripts to RNA or stability of the mRNA.
The ODC clone used in this thesis, pODC 10/2H, contains only a 
small part of the 5' end of the gene. It is likely, therefore, that 
any alterations of the UPEs, which are responsible for enhanced 
expression, will not be detected by these experiments.
4.7 ODC Expression in Other Tumours
ODC mRNA expression was higher in colorectal neoplasia than in 
gastric cancer and sarcomas, although the number of gastric and 
sarcoma samples examined was small. This may indicate tissue 
specific changes in ODC regulation which will require further study.
4.8 ODC DNA Analysis
It is well-known that amplification of the ODC gene can occur 
under certain circumstances, particularly polyamine deprivation and 
exposure to DFMO.138'140
A human myeloma (Sultan) cell line was also induced to amplify 
ODC in the presence of DFMO. The amplified signal which corresponded 
to 5.8 kb band on Hind III digests, and a 9 kb band in EcoRI digests 
was localised to chromosome 2 . 246,333 Another human myeloma cell line 
(Fravel), when exposed to DFMO, did not develop gene amplification, 
but was found to overproduce arginine.334
Although in the solid tumour experiments ODC mRNA expression 
was generally increased, no amplification or rearrangement of either 
ODC or either AdoMetDC locus was found implying that gene activation 
does not occur due to increased gene dosage or to translocation of 
the genes resulting in inappropriate expression.
Interestingly, using the restriction enzyme PstI, a restriction 
fragment length polymorphism was detected on chromosome 2. Two 
common alleles represented by 8.4 and 5.5 kb bands represent markers 
that will be useful in gene mapping family studies and for 
determining the association and expression of specific ODC alleles
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with tumours and for possibly predicting a tumour phenotype in 
families. One patient was observed with an ODC PstI digest phenotype 
that suggested that alteration of the chromosome 2 polymorphic site 
occurred. It is not implied that this alteration caused the tumour 
but suggests that these polymorphic markers can be used to study 
colorectal neoplasia.
The two hit theory of neoplasia developed by Knudson95 states 
that disease occurs due to two mutations at a single disease locus. 
In the case of familial tumours a constitutional or germ line 
mutation is unmasked by a later somatic mutation or deletion. This 
hypothesis was subsequently shown to be true for both 
retinoblastoma96*97 and Wilms tumour.98 Loss of heterozygosity has 
also been seen in acoustic neuroma,335 breast cancer,336 small cell 
lung cancer,337 ovarian cancer,338 and neuroblastoma.339
No loss of heterozygosity of the ODC loci was seen in 
colorectal neoplasia, indicating that removal of a tentative 
suppressor gene does not allow increased ODC expression in this 
system.
In two out of six patients with gastric tumours abnormalities 
of one of the chromosome 2 alleles was present (Figure 28). In lanes 
3 and 4 the tumour and mucosal DNA are depicted for one patient. The
8.4 kb allele is faint in the tumour and absent in the adjacent 
mucosa. This may represent possible contamination from another 
patient sample. In lines 5 and 6 the adjacent mucosa shows a faint
8.4 kb band which is absent in the tumour, the tumour tissue being 
homozygous. Since the 8.4 kb band is so faint in the normal tissue 
this may not represent a true loss of heterozygosity. Loss of 
heterozygosity has been reported to occur infrequently in gastric 
cancers,340 although chromosome 2 was not examined in that study.
4.9 AdoMetDC DNA Analysis
No amplification, rearrangement, or allelic loss was found in 
any of the tumours examined.
During stimulated growth, increases in AdoMetDC activity occur 
which are mainly due to increases in the amount of enzyme protein.
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There is both an increase in expression of AdoMetDC RNA and increased 
rate of translation.263
The human and rat genes have been cloned and show a high degree 
of homology, over 90%.261 Both contain a long untranslated 5' leader 
sequence. Very few genes have leader sequences greater than 200 
nucleotides, ODC being one of these. This has important implications 
for the methods of regulation of AdoMetDC.
Depletion of polyamines by DFMO leads to an increase in 
AdoMetDC activity due entirely to increases in amount of 
protein.261'341,342 A five-fold increase in synthesis rate was 
accompanied by a two-fold increase in mRNA implying alteration of 
both transcription and translation.343
Both AdoMetDC and ODC contain a strong "PEST" sequence, one or 
more regions rich in proline (P), glutamic acid (E), serine (S), and 
threonine (T). This region is believed to influence the fast rate of 
enzyme breakdown.344
AdoMetDC RNA is expressed as two RNA species (1.7-2.4 kb and 
3.0-3.6 kb). It is still unknown whether these are the results of 
two genes, or one gene subject to multiple polyadenylation signals.331
The regulation of the coordinate expression of ODC and AdoMetDC 
is still unknown. An increase in AdoMetDC activity usually follows 
ODC activity temporally. It is possible that trans-acting factors 
stimulated by increased ODC expression affect AdoMetDC transcription.
4.10 Correlations With Other Genes Expressed in Colon Cancer
Tricoli, et al.,86 reported a moderately high elevation of IGF-2 
mRNA levels in 40% of colorectal tumours examined. There was an 
obvious correlation with site of origin of the tumour: levels being
much higher for those of rectosigmoid origin than for cancers from 
the proximal colon. Dukes C tumours were noted to have a higher 
level of expression than Dukes B.
In this study, no correlation was found between IGF-2 
expression and ODC expression. Of the six colorectal neoplasia 
samples examined, only one polyp and one carcinoma (a rectal BII 
lesion) showed enhanced IGF-2 expression whereas all samples 
demonstrated increased ODC expression.
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This may indicate that IGF-2 expression occurs at a later stage 
of tumour progression than ODC expression, and may be more specific 
for metastatic potential of the cancer.
It is possible that enhanced IGF-2 expression is one of the 
variables accounting for differences in tumour biology between 
proximal and distal cancers.
4.11 The Chronology of Genetic Alterations in Colorectal Neoplasia
Over the past few years, there has been an exponential increase 
in knowledge concerning the molecular events in colon carcinogenesis.
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This was prompted by the recognition of the familial adenomatous 
polyposis (FAP) gene on chromosome 5. Subsequent work from the 
laboratories of Ray White, Bert Vogel stein, and Johannes Bos have 
helped to elucidate our current understanding of genetic alterations 
in colorectal neoplasia, particularly in relation to allelic loss on 
chromosomes 5, 17, and 18.
It is believed that cancer results due to a series of genetic 
alterations leading to a progressive disorder of the normal 
mechanisms which control cell growth.345-347 A neoplastic clone of 
cells develops enhanced genetic instability which increases the 
probability of further genetic alterations and subsequent 
progression.347 Such biologic characteristics of progression would 
be, for example, loss of differentiation, invasion, metastasis, and 
resistance to therapy.346
Analysis of age-incidence curves have suggested that three to 
four mutation-like changes are necessary for the development of 
leukemia and six to seven for carcinomas.348,349 One of the 
difficulties encountered in cancer research is determining which 
genetic changes are tumourigenic and which are random, occurring 
later on in tumour development.
Fearon, et al.,350 have demonstrated that colorectal tumours are 
clonal in origin. Studies of colorectal polyps have helped greatly 
in defining the chronology of subsequent genetic changes leading to 
progression. Since polyps are the premalignant precursors of 
colorectal cancer, any genetic alterations seen in polyps are likely 
to be involved in the early stages of oncogenesis.
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4.11.1 Hvpomethvlation
DNA hypomethylation can result in increased gene 
activity.202 Feinberg and Vogel stein have shown that numerous 
genes (e.g., growth hormone, gamma globulin, alpha globulin, 
Harvey Ras, and c-myc) are hypomethylated in 100% of colon 
cancers.89,351,352 Hypomethylation also occurred to an equal 
degree in benign polyps thus hypomethylation precedes the 
development of malignancy,353*354 and may be one of the earliest 
changes in the oncogenic cascade.
The expression of ODC is also altered by changes in 
methyl ation.
Alhonen-Hongisto, et al., found that the ODC of the cells 
of a human lymphatic B-cell leukaemia were significantly 
hypomethylated, compared to mononuclear leucocytes or a human 
myeloma (Sultan) cell line.244 Lipsanen, et al.,355 have shown 
hypomethylation of ODC from blood samples of patients with 
chronic lymphatic leukaemia (CLL). Since an increase in ODC 
activity was noted in lymphocytes from patients with CLL 
compared to normal lymphocytes,356 it is possible that altered 
methylation is one mechanism for gene deregulation in this 
disease. Such hypomethylation of ODC is not seen in chronic or 
acute myeloid leukemia or polycythemia rubra vera.357 Other 
work has shown that ODC hypomethylation in mouse L1210 leukemia 
cells may account for increased gene expression in the absence 
of gene amplification.358,359
The essential nature of methyl at ion state on expression of 
the ODC gene was demonstrated in experiments by Halmekyto, et 
al. Methylation of ODC prior to transfection in Chinese 
hamster ovary cells was found to abolish transient expression 
of the gene.360
Since it is well-known that ODC levels increase in 
response to TPA, Hsieh and Verma361 studied the relationship 
between hypomethylation and the response to TPA in a human 
bladder carcinoma cell line. They found that application of 
TPA produces no change in methylation of the gene, although a 
consistent increase in ODC levels results. Changes in
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methylation status of other genes usually occur in the 5' 
flanking end containing regulatory sequences.361,362 The pODC 
10/2H clone used by Hsieh and Verma contains only 87 bp of the 
5' end. Different results may be obtained with a full-length 
clone.
Insight into how hypomethylation may result in a sequence 
of further genetic events was provided by Schmid, et al.363 
Hypomethylation was shown to inhibit chromosome condensation - 
this may lead to mitotic nondysjunction resulting in the loss 
or gain of chromosomes.
Further study of methylation status of the ODC gene in 
colon cancers and other solid tumours should now be performed 
using the full-length ODC clones containing all of the 5' end.
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4.11.2 Ras Gene Mutations
Alterations in the ras genes in colon neoplasia has been 
noted by a number of authors. Spandidos and Kerr84 found 
enhanced expression of both Ki-ras and Ha-ras in polyps and 
carcinoma. Increased Ha-ras protein in colon cancers was also 
seen by Hand, et al.364 Amplification and rearrangement of ras 
genes has not been found.365 Although hypomethylation of ras 
genes does occur in colon neoplasia,89 other mechanisms of 
activation also occur.
The most frequently observed ras mutation is of the 
Kirsten-ras gene which is altered in about 50% of colon tumours 
and premalignant lesions,366,367 the predominant mutation being 
at position 12.
Bert Vogel stein, in collaboration with Roy White and 
Johannes Bos, has elucidated further the involvement of ras 
mutations in the transition from benign to malignant neoplasia. 
Ninety-two carcinomas and 80 adenomas were studied.368 The 
adenomas were divided into three classes: Class I - small
tubular adenomas with low grade dysplasia from patients with 
FAP; Class II - polyps without evidence of carcinoma from 
patients without FAP; Class III - polyps containing areas of 
carcinoma from patients without FAP.
t:
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Eighty-eight percent of all the ras mutations found were 
of the K-ras gene, predominantly codons 12, 13, and 61. There 
was no correlation between site of tumour, Dukes stage, degree 
of differentiation, or age or sex of the patient.
The Class II and III adenomas contained ras mutations as 
frequently as carcinomas, however, the small low grade adenomas 
of Class I contained mutations much less frequently. A much 
higher proportion of polyps with high grade dysplasia contained 
mutations. Of note, only 9% of polyps less than 1 cm in 
diameter contained mutations compared to 70% greater than 2 cm. 
This suggests that mutations of the ras gene are involved in 
the progression of polyps from low to high grade dysplasia. 
Ras mutations are not the initiating factor in colon neoplasia 
since they are not seen frequently in low grade adenomas.
Burmer and Loeb369 demonstrated that Ki-ras mutations preceded 
changes in ploidy in colon carcinomas.
Mutations of the ras genes, resulting in an altered 
protein product (p21) can alter signal transduction by at least 
two mechanisms: 1) When a growth factor binds to its
receptor, a cytoplasmic G protein (such as the ras product) 
binds GTP and attaches to the membrane by a fatty acid tail. 
PLC is then stimulated resulting in cleavage of PIP2 to ITP3 and 
DAG. DAG activates PKC in conjunction with calcium. PKC 
results in protein phosphorylation on threonine or serine
residues and enhances expression of c-myc and c-fos; and, 2) 
G proteins are necessary for signal transduction via the 
adenylate cyclase pathway. Binding of molecules to the 0-
adrenergic receptor in the presence of G protein activates
adenylate cyclase, increases levels of cAMP, which produces 
activated PKA. PKA then produces protein phosphorylation and 
enhanced expression of nuclear oncogenes.
Mutation of the ras gene results in enhanced ODC 
expression. Holtta, et al.,370 studied ODC expression in NIH 
3T3 cells transformed with human C-Ha-ras. They found much 
higher levels of ODC in the transformed compared to normal 
cells. Furthermore, ODC was maintained at a constituitively 
high level, with loss of normal cell cycle control. Increased
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ODC expression was due to altered mRNA processing or turnover 
and not to enhanced transcription. Sistonen, et al., noted 
that levels of ODC expression were dependent on mutant ras gene 
copy number.371
Further evidence of the transforming activity of mutated 
ras protein was provided by work by Wasylyk and Imler,372,373 on 
the transcription factor which binds to ras. A ras responsive 
element (RRE) has been identified in the polyoma virus. This 
sequence also mediates activation by TPA and serum and is a 
binding site for the mouse transcription factor PEA 1. PEA 1 
is a homologue of AP-1 and c-jun. It is thought that PEA 1 
belongs to a closely related family of transcription factors 
which includes human AP-1 , the v-jun oncogene and yeast GCN4. 
Thus, it appears that altered ras product p21 may bind to the 
AP-1 site of the ODC gene and result in increased expression. 
Mutated p21 may also activate ODC via' its cAMP responsive 
element. Sistonen, et al.,374 studying NIH 3T3 cells 
transfected with mutated c-Ha-ras have provided further support 
for this idea. ODC mRNA was enhanced following induction of 
p21 c-Ha-ras protein. Two other serum and tumour-promoter 
regulator genes were also increased-transin and the glucose 
transporter. The high level of expression of ODC was 
insensitive to tumour-promoter stimulation suggesting that the 
TPA responsive site was already maximally stimulated by ras.
It is now accepted that the AP-1 site is the product of 
the nuclear protooncogene jun.375 The product of the fos 
protooncogene (p55 fos) is also related to AP-1. It appears 
that cooperation between fos and jun is required for full 
activation of transcription via the TPA-responsive elements.376
4.11.3 Chromosome 5
A major breakthrough in the study of colorectal cancer was 
the mapping of the familial adenomatous polyposis (FAP) gene to 
chromosome 5. In 1986, A. A. Sandberg's lab at Roswell Park 
Cancer Institute published a report of a patient with Gardner's 
syndrome who had a constitutional deletion of the long arm of
92
chromosome 5.377 Following this report, two laboratories 
working independently mapped the FAP gene to the long arm of 
chromosome 5.378,379 More recently, the locus has been defined 
to reside at 5q21-22.380,381 Approximately 20% of familial and 
sporadic colon carcinomas showed loss of heterozygosity of the 
FAP locus.382-384 Vogel stein, et al.,368 found allelic loss on 
chromosome 5 in 36% of carcinomas and 29% of both Class II and 
III adenomas. However, the tubular low grade adenomas of 
patients with FAP (Class I adenomas) revealed no losses on 
chromosome 5. This finding is not compatible with Knudson's 
model of suppressor genes. Vogel stein hypothesises that the 
FAP locus is involved in epithelial hyperproliferation of the 
colonic mucosa and that a mutation of only one of the alleles 
is necessary for activation to occur. He suggests that further 
genetic alterations, for example, deletions of 17 and 18 are 
necessary to complete the transformation to malignancy. Law, 
et al.,385 also believe that the FAP locus acts in a dominant, 
not a recessive, manner. Two synchronous colon cancers from a 
patient with FAP did not lose the chromosome 5 allele.
4.11.4 Chromosomes 17 and 18
In comparison with allelic loss of chromosome 5, deletions 
of chromosomes 17 and 18 occur much more frequently, in the 
range of 40-75% of carcinomas.368,385-387 In contrast, deletions 
in adenomas occur in 6-47% of cases.368 Deletions of 17p and 
18q were uncommon in Class I and II adenomas, though allelic 
deletions of 18q occurred in about 50% of class III adenomas. 
Thus, it appeared that deletions of chromosome 5 and ras gene 
mutations precede deletions of 18q, which in turn precede 
allelic losses of chromosome 17. This is confirmed by looking 
at the accumulation of genetic changes in adenomas compared to 
carcinomas. Only 9% of Class I adenomas had more than one 
genetic change, however, over 90% of carcinomas had two or more 
genetic alterations.
The chronology of genetic changes was studied by 
Vogel stein using an elegant microdissection technique. The
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benign areas of Class III adenomas were separated from the 
carcinomatous elements and the DNA extracted separately. In 
general, alterations of ras and chromosome 5 occurred before 
chromosome 18q deletions in the same patient. There were a few 
exceptions, however, suggesting that it is the accumulation of 
genetic changes over time rather than their exact sequence, 
which is important in colon neoplasia.368
Vogel stein's group has also coined the term fractional 
allelic loss (FAL)388 to describe the number of chromosomal arms 
on which allelic loss was observed divided by the number of 
chromosomal arms for which allelic markers were informative in 
the patients' normal c e l l s . T h e  median FAL of 56 colorectal 
tumours was 0.20. A significant finding was that a higher FAL 
was associated with a poorer prognosis. Thirty percent of 
patients with FAL less than 0.2 had recurrence of tumour 
compared to 68% with FAL greater than 0.2. Similarly, the 
figures for death from disease were 26% versus 64%. These 
figures were independent of Dukes stage. A follow-up study389 
confirmed the above and found that distant metastases were 
significantly associated with a high FAL. Ras mutations and 
chromosome 5 deletions did not have prognostic significance, 
but FAL was associated with 17p and 18q deletions. Allelic 
deletions of 17p were more common in left-sided than right­
sided tumours. It appears that 17p and 18q deletions are 
markers of tumour aggressiveness and indicate metastatic 
potential. Delattre, et al.,390 also noted a higher frequency 
of 17p and 18q deletions in distal compared to proximal colon 
cancers.
The site of chromosome 17 deletion has been localised to 
17pl2-17pl3.3. This region contains the gene for the 
transformation associated protein p53. Baker, et al.,387 
confirmed that mutations of this locus result in enhanced p53 
expression in colorectal carcinoma. Enhanced p53 expression 
has been noted in 55% of colon cancers compared to 8% of 
tubular adenomas. Enhanced expression correlated with areas of 
dysplasia.391 Mutations of the p53 gene occur in many other
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tumour types, e.g., lung, breast, and brain and are not 
exclusive to colon cancer.392-394
For a gene to be a tue suppressor gene, the presence of 
the normal wild type allele should prevent transformation. 
This has been shown to be true for the Wilms tumour locus on 
chromosome ll.395 The transformation of primary rat embryo 
fibroblasts is prevented by addition of the wild type p53 
gene.396 Colon adenoma cell lines containing the wild type p53 
do not have tumourigenic activity.397 Thus, p53 acts as a true 
suppressor gene.
The second most common region of allelic loss in 
colorectal tumours is 18q, which is lost in 44-73% of 
colorectal carcinomas.368,388,390,398,399 Loss of this region in 
Class I and II adenomas is much less frequent, 13 and 11%, 
respectively, but occurs in 47% of late stage adenomas.368 
Vogelstein's studies using microdissection of Class III 
adenomas reveal that allelic deletions of 18q generally occur 
at a later stage than deletions of 5q and precede changes of 
17p. The DNA for the consistently deleted region on 18q has 
now been cloned400 and identified as a candidate tumour 
suppressor gene termed DCC (deleted in colorectal carcinoma).
The predicted amino acid sequence of DCC suggests that the 
protein is related to molecules involved in cell adhesion. 
Thus, the gene may play a role in normal cell to cell 
interactions or interactions with the extracellular matrix 
which may be necessary for metastasis.
The region on chromosome 18 is particularly interesting in 
that Lynch syndrome II, hereditary nonpolyposis colorectal 
cancer (HNPCC) is linked to the Kidd blood group. Both genes 
have been mapped to 18q.401,402 It will be important to know 
how DCC and HNPCC genes relate and if they are in fact the same 
locus.
The recognition of the accumulation of genetic changes 
necessary for colorectal cancer to occur has led Vogel stein's 
group to propose a model of tumouri genes is403 (Figure 31). 
Mutations of the FAP gene on chromosome 5 may give rise to the 
general hyperproliferation which precedes adenoma formation.
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Hypomethylation then contributes to the general instability of 
the genome at an early stage of adenoma formation. Alterations 
of the ras genes, particularly K ras, are responsible for 
changes in signal transduction which result in progression to 
a later stage of adenoma. The deletions of 18q and 17p with 
concomitant loss of suppressor gene function then result in 
carcinoma formation, 18q deletion generally occurring before 
17p deletions. Other mutations are believed to account for the 
development of the metastatic phenotype.
The tumourigenic phenotype is distinct from the metastatic 
phenotype and "metastasis suppressor genes" have been proposed 
which function in the same manner as the recessive genes 
involved in tumour formation.404 Metastasis is a multi step 
process involving invasion of intercellular matrices, 
penetration of the basement membrane, extravasation, and 
induction of angiogenesis in the target organ. Metastasis also 
involves the coordinated expression of gene products. One of 
the first steps is attachment via cell-surface receptors to 
components of the basement membrane, e.g., 1 aminin.404,405 
Laminin expression is increased in colorectal carcinoma.406 
Laminin increases the release of type IV collagenase which 
would thus permit invasion through the matrix.407 Metastatic 
potential is known to be related to the MHC genes, which in 
turn appear to be regulated by the nuclear oncogene c-fos.408,409
In addition to the allelic deletions in Vogelstein's 
model, other gene products are consistently altered in 
colorectal carcinomas. An example would be c-myc. The product 
of c-myc is a transcriptional activator which can act upon 
cellular genes and thereby alter growth control.410 Elevated c- 
myc expression occurs in approximately 70-80% of colorectal 
cancers,411,412 in the absence of rearrangement or amplification. 
Amplification has been reported in colon cancer cell lines, 
however.100
Higher c-myc mRNA levels were associated with cancers of 
the distal rather than proximal colon.413 Deregulation of c-myc 
appears to be associated with deletion of the FAP locus. 
Forty-seven percent of tumours with elevated expression of c-
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myc exhibited allelic loss on 5q, compared to 0/8 tumours with 
normal c-myc expression,414 thus, cooperation between gene loci 
may exist.
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Figure 31
The Model of Colorectal Tumourigenesis 
Colorectal cancer develops through a series of genetic alterations involving 
tumour suppressor genes (particularly on chromosomes 5, 17, and 18) and 
oncogenes (RAS). Accumulation of these changes gives rise to increasingly 
large polyps which eventually become malignant.
4.11.5 ODC in the Model of Colorectal Tumourigenesis
A normal resting population of animal cells exists in the 
G0 state. Activation by mitogens induces the cells to enter 
the G, phase and then progress through DNA synthesis to cell 
division. Genes which are involved in the transition from G0 
to G1 are said to be under "growth control" whereas those which 
operate in G1 to M are under "cell cycle control".306 Clearly, 
one of the key questions to be answered in cancer research is 
to identify the growth control genes which activate the cell 
from its resting to transformed state.415 Evidence points to 
ODC and AdoMetDC as being growth controlled genes, whereas 
histone mRNAs, for example, are under cell cycle control.306 
This contradicts earlier reports that ODC was elevated mainly 
in late G1 and S.111 Elevation of ODC mRNA is one of the 
earliest changes seen upon ligand binding to cell surface 
receptors.
Sistonen, et al.,416 studying the neu tyrosine kinase 
receptor found that one of the early changes induced by 
receptor activation was induction of the fos/jun transcription 
factor complex, closely followed by an increase in ODC mRNA. 
The elevation of ODC expression is thought to be mediated by 
the AP-1/PEA 1 transcription factor which is known to exist 
among the 5' regulatory sequences of the ODC gene. The 
elevated expression of ODC mRNA after the induction of mutated 
p21 c-Ha-ras oncoprotein,376 which may be mediated via the 
fos/jun transcription factor complex, also lends support to the 
idea that ODC is involved in the early stages of the colon 
carcinogenesis model. ODC is likely to be involved in the 
general hyperproliferation of cells as they move from a resting 
to an active state, and in the progression of adenomas from 
early to intermediate stage associated with mutations of the 
ras genes. Mutated ras genes may influence ODC in both AP-1 
and cAMP regulatory sequences. Ras and ODC may cooperate in 
the early stages of tumourigenesis, since ras mutations enhance 
ODC expression.370,371
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In this thesis, ODC expression was elevated in both 
tubular, tubulovillous, and villous adenomata, i.e., early, 
intermediate, and late stages. This also promotes ODC as an 
integral part in early tumourigenesis.
The global hypomethylation of genes which occurs in 
polyps, as well as carcinomas, is known to inhibit chromosome 
condensation and may lead to mitotic nondysjunction. Such 
genetic instability may lead to further loss of regulation of 
a number of genes, including ODC. It has been demonstrated 
that altered methylation of ODC is essential for its full 
expression in some systems.360 Alterations in DNA methylation 
of the promoter regions is known to alter gene transcription.417 
The possible cooperation of ODC with other genetic changes 
known to operate in colorectal oncogenesis is depicted in 
Figure 32.
The integral part played by ODC and AdoMetDC in the 
carcinogenesis cascade is emphasized by the effect of the 
polyamines on gene transcription. Celano, et al.,418 
demonstrated that depletion of ODC by DFMO resulted in a 90% 
decrease in c-myc expression. A subsequent study419 using a 
colon carcinoma cell line revealed that polyamines can also 
regulate the expression of the c-fos and hi stone 2-A genes. 
The mechanism of polyamine regulation of gene transcription is 
by several mechanisms: alterations of chromatin condensation, 
increased DNA stability, and a conformational change from 0- to 
Z-DNA.419 Structural changes in chromatin and nucleosomes 
induced by polyamines may result in increased availability of 
DNA for transcription.420 This may be mediated by altered 
binding of transcriptional regulatory factors.421
Binding of spermine to 0-DNA (a right-handed helix) 
results in a conformational change to Z-DNA (a left-handed 
helix).422,423 Spermine increases stability of /J-DNA by a 
decrease in the size of the major groove of DNA and an increase 
in the minor groove, with subsequent change in the tertiary 
structure.121 Polyamines stabilise Z-DNA better than 0-DNA. 
Such conformational changes at the 5' regulatory end of the 
gene can be predicted to enhance gene transcription.424
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ODC in the Model of Colorectal Tumourigenesis 
ODC is involved early in colorectal tumourigenesis, an elevation in 
expression being seen soon after ligand binding to receptor on the cell 
membrane. Elevated ODC is essential for cell growth and proliferation. 
Altered methyl at ion is known to activate the ODC gene. Mutation of the p21 
as protein also activates the ODC gene. The effect of polyamines on gene 
transcription may also be involved in further genetic changes as cancer 
progresses to metastasis.
Polyamines can alter transcription then by acting as 
chromatin openers and by altering the conformation of promoters 
and enhancers.425 Changes in transcription, due to alterations 
in RNA elongation, may also account for the effect on c-myc 
expression.426
ODC and AdoMetDC exhibit coordinate expression in general. 
The fact that their loci exist on different chromosomes may 
indicate that trans-acting factors stimulated by ODC affect 
transcription of the AdoMetDC gene. The other polyamines then 
produced by the activity of AdoMetDC may then go on to promote 
expression by other cancer related genes.
It is also possible that the regulatory sequences at the 
5' end of the AdoMetDC gene have some features in common with 
ODC and respond to the same stimuli. Examples would be a 
glucocorticoid recognition site and AP-1 and AP-2 transcription 
factors. It is known that the AdoMetDC gene contains a long 5' 
noncoding region,261 but the exact nature of the regulatory 
sequences will not be known until the full-length genomic DNA 
is cloned.
ODC expression was noted to be higher in colorectal cancer 
than other malignancies, e.g., breast and sarcoma. The nature 
of tissue specific gene regulation is largely unknown. Recent 
works on the albumin gene indicates the presence of particular 
transcription binding sites (CHNF-1 and C/EBP) which act in a 
tissue specific manner.427 It is likely that such variation in 
transcription binding sites also accounts for the differences 
seen with ODC expression. Cis-acting regulatory sequences also 
account for globin expression only in erythroid cells.428
4.11.6 Clinical Applications of Polyamine Research
Because ODC appears to be so essential for tumour growth 
and maintenance, it is not surprising major developments are 
taking place in the research and development of ODC inhibitors 
in cancer chemotherapy. Since the discovery of DFMO by 
Metcalf,116 numerous inhibitors of the polyamine pathway429 have 
been devised including ornithine analogues,430*431 putrescine
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analogues,432 spermine and spermidine synthases inhibitors,433 
diamine oxidase and polyamine oxidase inhibitors,434 AdoMetDC 
inhibitors,137,435'436 and spermidine derivatives.437
The irreversible inhibitor of ODC, DFMO, has been shown to 
act in a synergistic fashion with several other antineoplastic 
drugs. The combination of DFMO with the S-phase specific drug 
ara-C, an inhibitor of DNA polymerase, resulted in preferential 
tumour cell kill in vivo and in vitro.438 DFMO will also act 
synergistically with hydroxyurea (an inhibitor of 
ribonucleotide reductase).439
The activity of the alkylating agent BCNU is enhanced by 
polyamine depletion via DFMO.440 Such synergism is thought to 
be due to changes in DNA conformation brought about by lack of 
polyamines.
The combination of DFMO with 5FU441 and with mitomycin C442 
are also synergistic in action against colon cancer cell lines. 
In theory, the combination of an ODC inhibitor with an AdoMetDC 
inhibitor (Figure 2) should result in greater polyamine 
depletion and hence increased efficacy - this was found to be 
the case. The use of DFMO with MGBG (an inhibitor of AdoMetDC) 
resulted in four-fold increase in toxicity to Hela cells.438 
Similar results are obtained with other AdoMetDC inhibitors.443
The first clinical trial using DFMO with MGBG was on five 
children with advanced leukemia. An impressive response 
occurred with mild toxicity. Responses have also been seen 
with this regimen in Hodgkin's disease, lymphoma, sarcoma, and 
thyroid carcinoma. Ten out of 16 patients with recurrent 
astrocytoma responded to this drug combination.444
Our knowledge of the polyamine biology of certain tumours 
may help to predict the response to single therapy with DFMO. 
Casero, et al.,445 have shown that human lung tumour sensitivity 
to DFMO is related to ODC mRNA steady state levels - the lower 
the ODC mRNA, the more likely the response to DFMO.
The finding that ODC mRNA levels were higher in colon 
neoplasia than gastric carcinoma and sarcoma may indicate that 
ODC inhibitors will be more effective in therapy of the latter 
two tumour types.
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Since toxicity from DFMO is low, the prophylactic use of 
this agent in patients at high risk of colorectal cancer or 
patients with multiple polyps may be considered. Luk and 
Baylin also suggested its use in the relatives at risk of 
familial adenomatous polyposis or patients with FAP who have 
undergone colectomy without proctectomy.188
Kingsnorth, et al.,446 noted that polyamine levels in 
breast cancer were correlated with poor prognostic factors such 
as histologic grade and oestrogen receptor negative status. 
Thomas447 has shown that ODC mRNA levels in hormone unresponsive 
breast cancer were two- to four-fold higher than in hormone 
responsive cancer. This finding may again be related to the 
DNA interactions of the polyamines - Thomas and Kiang448 showed 
that polyamines are capable of modulating the binding of 
progesterone receptor to DNA, thus playing a role in gene 
regulation in breast cancer.
Antioestrogen therapy with tamoxifen and 4-hydroxy- 
amoxifen reduced ODC mRNA expression in the hormone responsive 
breast cancer cell line MCF-7.449 This is likely to be due to 
down regulation of oestrogen responsive elements of the ODC 
gene.
4.11.7 Closing Remarks
Despite the great inroads into the molecular biology of 
colon cancer seen in the past few years, many questions are 
still to be answered. For example, what is the relationship 
between the familial aspects of colon cancer and carcinogens 
such as bile acids? This is complicated even more by the 
discovery by Watne, et al.450 that FAP patients had higher 
concentrations of cholesterol and bile acids in their stools. 
How do dietary factors influence gene regulation? LI or et 
al,451 have shown that increased dietary calcium can reduce the 
incidence of K-ras mutations in carcinogen-induced colon 
cancer.
Cannon-Albright, et al.,452 have determined that inherited 
susceptibility to colon cancer is much more frequent than
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previously thought. Susceptibility to polyps and cancer 
probably account for the majority of colon cancers, with a gene 
frequency of 19%. Leppert, et al.,453 have discovered that the 
susceptibility gene in patients with a family history of colon 
cancer is located on chromosome 5 at or very near the FAP 
locus. Recently, Kinzler and colleagues454 in Vogelstein's 
laboratory have identified the putative suppressor gene located 
at 5q21 in sporadic colon cancers. The gene, which they term 
MCC (mutated in colon cancer) has homology with the G protein- 
activating region of the muscarinic acetylcholine receptor. 
This discovery is fascinating, bearing in mind the role of the 
ras proteins, which are members of the G protein family, in 
signal transduction and colon tumourigenesis.
It is likely that Hill15 was correct in that an 
environmental carcinogen can only cause progression to the 
neoplastic state when genetic predisposition is present.
Knowledge of the molecular cascade involved in colon 
cancer opens many new approaches for chemotherapy. For 
example, drugs which inhibit binding of fatty acids to the 
tails of ras protein, such as compactin or lovastatin, would 
prevent activation of second messengers. Monoclonal antibodies 
to growth factor receptors are known to decrease tumour growth. 
Tyrophostins are a new class of drugs which competitively 
inhibit the tyrosine kinase domain of GFRs.297 Molecular 
antineoplastic therapy is now at hand. These drugs could be 
used alone or in combination with ODC and AdoMetDC inhibitors 
for a synergistic effect.
Further research into the specific molecular steps 
involved in colorectal cancer tumourigenesis can only increase 
the specificity of therapy we have for the disease.
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4.11.8 Conclusions
1. The ODC gene maps to 2p25 and 7q31-+qter. Preliminary data 
suggests the locus on chromosome 2 to be functional.
2. The AMD gene maps to a locus on chromosome 6 and to Xq22- 
Xq28.
3. Polymorphism of the ODC gene between individuals was seen 
with PstI digests. Allele frequencies conform to the 
Hardy Weinberg law with p = 0.28 and q = 0.72.
4. Increased expression of the ODC gene is seen in both
benign and malignant colorectal neoplasia when compared to 
adjacent mucosa. In polyps, the mean increase is 3.2-fold 
and in carcinomas, 4.2-fold.
5. When ODC activity and mRNA expression are compared for the
same tissue sample, no correlation is seen. As ODC
activity and amount of protein present are generally
parallel, this implies that post-transcriptional factors 
account for altered activity. Possible examples would be 
altered translatability of the RNA or posttranslational 
modifications of the protein.
6. ODC expression was higher in colorectal neoplasia than in 
gastric carcinoma or sarcomas. This may indicate that 
tissue-specific mechanisms of gene regulation are in 
operation.
7. No amplification or rearrangement of either ODC locus or 
either AMD locus was seen consistently in colorectal 
neoplasia. No amplification or rearrangement of ODC was 
seen in sarcomas, breast carcinoma, lung carcinoma, or 
gastric carcinoma.
8. No correlation was found between ODC expression and IGF-2 
expression.
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APPENDIX
Solutions and Buffers
SSC - Standard sodium citrate; 20 x SSC is 3MNaCl, 0.3 MNa3 citrate pH 7. 
Denhardt's solution; 50x: Ficoll 5g
polyvinylpyrrolidone 5g 
BSA (Pentax fraction V) 5g 
H20 to 500 ml
Nick translation buffer lOx: 0.5 M Tris HC1 pH 7.8
0.05 M MgCl2 
0.1 M a-mercaptoethanol 
DNase I activation buffer: 10 mM Tris HC1 pH 7.6
5 mM MgCl2
1 mg/ml nuclease free BSA 
Random priming buffer: RPRB 2.5 x comprises
Hepes pH 6.6 0.5 M 
MgCl2 12.5 mM 
/J-mercaptoethanol 0.025 M 
Tris pH 8.0 0.125 M 
3x d NTP 50 mM 
DNase I: 1 mg/nl in 0.1 N HC1
Buffer A: BSA 0.5%
Na2 EDTA 1 mM 
SDS 5%
NaHP04 pH 6.8 40 mM 
Buffer B: Na2 EDTA 1 mM
SDS 1%
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